TW311091B - - Google Patents
Download PDFInfo
- Publication number
- TW311091B TW311091B TW082100545A TW82100545A TW311091B TW 311091 B TW311091 B TW 311091B TW 082100545 A TW082100545 A TW 082100545A TW 82100545 A TW82100545 A TW 82100545A TW 311091 B TW311091 B TW 311091B
- Authority
- TW
- Taiwan
- Prior art keywords
- emulsion
- emulsions
- carbon atoms
- compound
- patent application
- Prior art date
Links
- 239000000839 emulsion Substances 0.000 claims abstract description 203
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 20
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract description 19
- 239000000203 mixture Substances 0.000 claims abstract description 19
- 239000001301 oxygen Substances 0.000 claims abstract description 19
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 19
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 18
- 150000001875 compounds Chemical class 0.000 claims description 61
- 210000002969 egg yolk Anatomy 0.000 claims description 25
- 239000003921 oil Substances 0.000 claims description 25
- 235000019198 oils Nutrition 0.000 claims description 25
- 235000013345 egg yolk Nutrition 0.000 claims description 19
- 108010000912 Egg Proteins Proteins 0.000 claims description 18
- 102000002322 Egg Proteins Human genes 0.000 claims description 18
- 235000019485 Safflower oil Nutrition 0.000 claims description 17
- 235000005713 safflower oil Nutrition 0.000 claims description 17
- 239000003813 safflower oil Substances 0.000 claims description 17
- 239000004094 surface-active agent Substances 0.000 claims description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 14
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 14
- 239000007788 liquid Substances 0.000 claims description 11
- 125000002015 acyclic group Chemical group 0.000 claims description 10
- 238000011049 filling Methods 0.000 claims description 10
- NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 claims description 8
- 235000013336 milk Nutrition 0.000 claims description 5
- 239000008267 milk Substances 0.000 claims description 5
- 210000004080 milk Anatomy 0.000 claims description 5
- 239000003549 soybean oil Substances 0.000 claims description 4
- 235000012424 soybean oil Nutrition 0.000 claims description 4
- 239000012530 fluid Substances 0.000 claims description 3
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 2
- 239000005642 Oleic acid Substances 0.000 claims description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 2
- 235000013601 eggs Nutrition 0.000 claims description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 2
- 239000008347 soybean phospholipid Substances 0.000 claims description 2
- BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 claims 3
- 229960003132 halothane Drugs 0.000 claims 3
- -1 cyclic organic compounds Chemical class 0.000 abstract description 26
- 238000000034 method Methods 0.000 abstract description 23
- 150000002894 organic compounds Chemical class 0.000 abstract description 12
- 206010028980 Neoplasm Diseases 0.000 abstract description 11
- 201000011510 cancer Diseases 0.000 abstract description 8
- 208000010125 myocardial infarction Diseases 0.000 abstract description 6
- 230000008569 process Effects 0.000 abstract description 6
- 239000002671 adjuvant Substances 0.000 abstract description 5
- 238000002512 chemotherapy Methods 0.000 abstract description 5
- 238000007887 coronary angioplasty Methods 0.000 abstract description 5
- 238000011282 treatment Methods 0.000 abstract description 5
- 239000003633 blood substitute Substances 0.000 abstract description 4
- 238000002595 magnetic resonance imaging Methods 0.000 abstract description 4
- 230000005855 radiation Effects 0.000 abstract description 4
- 238000002604 ultrasonography Methods 0.000 abstract description 4
- 230000002792 vascular Effects 0.000 abstract description 4
- 238000005481 NMR spectroscopy Methods 0.000 abstract description 3
- 238000002591 computed tomography Methods 0.000 abstract description 3
- 238000012984 biological imaging Methods 0.000 abstract description 2
- 238000003325 tomography Methods 0.000 abstract description 2
- 239000002872 contrast media Substances 0.000 abstract 1
- 229940039231 contrast media Drugs 0.000 abstract 1
- 210000004185 liver Anatomy 0.000 description 47
- 230000001954 sterilising effect Effects 0.000 description 42
- 238000004659 sterilization and disinfection Methods 0.000 description 41
- 206010014561 Emphysema Diseases 0.000 description 38
- 230000010412 perfusion Effects 0.000 description 34
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 31
- 241000282520 Papio Species 0.000 description 27
- 239000007789 gas Substances 0.000 description 25
- 229960001217 perflubron Drugs 0.000 description 21
- WTWWXOGTJWMJHI-UHFFFAOYSA-N perflubron Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)Br WTWWXOGTJWMJHI-UHFFFAOYSA-N 0.000 description 20
- 241000699670 Mus sp. Species 0.000 description 18
- 150000002222 fluorine compounds Chemical class 0.000 description 18
- 230000000694 effects Effects 0.000 description 15
- 235000011187 glycerol Nutrition 0.000 description 15
- 239000012298 atmosphere Substances 0.000 description 14
- 210000004072 lung Anatomy 0.000 description 14
- 241000700159 Rattus Species 0.000 description 13
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 13
- 238000001990 intravenous administration Methods 0.000 description 12
- 239000000126 substance Substances 0.000 description 12
- 231100000331 toxic Toxicity 0.000 description 12
- UVWPNDVAQBNQBG-UHFFFAOYSA-N 1,1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9,9-icosafluorononane Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F UVWPNDVAQBNQBG-UHFFFAOYSA-N 0.000 description 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 11
- 230000002079 cooperative effect Effects 0.000 description 11
- 239000002504 physiological saline solution Substances 0.000 description 11
- 230000002588 toxic effect Effects 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 10
- 229920006926 PFC Polymers 0.000 description 10
- 230000029058 respiratory gaseous exchange Effects 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 231100000419 toxicity Toxicity 0.000 description 10
- 230000001988 toxicity Effects 0.000 description 10
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 9
- 229910052731 fluorine Inorganic materials 0.000 description 9
- 239000011737 fluorine Substances 0.000 description 9
- 239000004615 ingredient Substances 0.000 description 9
- 238000002156 mixing Methods 0.000 description 8
- 150000004812 organic fluorine compounds Chemical class 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- 208000006011 Stroke Diseases 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 238000001802 infusion Methods 0.000 description 7
- 238000003860 storage Methods 0.000 description 7
- 230000004083 survival effect Effects 0.000 description 7
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 6
- 239000002473 artificial blood Substances 0.000 description 6
- 125000004429 atom Chemical group 0.000 description 6
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 6
- 229910052794 bromium Inorganic materials 0.000 description 6
- 229910052799 carbon Inorganic materials 0.000 description 6
- 239000000460 chlorine Substances 0.000 description 6
- 229910052801 chlorine Inorganic materials 0.000 description 6
- 238000002309 gasification Methods 0.000 description 6
- YVBBRRALBYAZBM-UHFFFAOYSA-N perfluorooctane Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F YVBBRRALBYAZBM-UHFFFAOYSA-N 0.000 description 6
- 239000002243 precursor Substances 0.000 description 6
- 238000001959 radiotherapy Methods 0.000 description 6
- 235000002639 sodium chloride Nutrition 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- 241001504519 Papio ursinus Species 0.000 description 5
- 206010053648 Vascular occlusion Diseases 0.000 description 5
- 238000003682 fluorination reaction Methods 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- QKENRHXGDUPTEM-UHFFFAOYSA-N perfluorophenanthrene Chemical compound FC1(F)C(F)(F)C(F)(F)C(F)(F)C2(F)C3(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C3(F)C(F)(F)C(F)(F)C21F QKENRHXGDUPTEM-UHFFFAOYSA-N 0.000 description 5
- 230000032258 transport Effects 0.000 description 5
- 208000021331 vascular occlusion disease Diseases 0.000 description 5
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 4
- 241000283984 Rodentia Species 0.000 description 4
- 108010090932 Vitellogenins Proteins 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000002399 angioplasty Methods 0.000 description 4
- 239000000306 component Substances 0.000 description 4
- 239000006210 lotion Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 238000002844 melting Methods 0.000 description 4
- 230000008018 melting Effects 0.000 description 4
- BKIMMITUMNQMOS-UHFFFAOYSA-N nonane Chemical compound CCCCCCCCC BKIMMITUMNQMOS-UHFFFAOYSA-N 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 229950011087 perflunafene Drugs 0.000 description 4
- UWEYRJFJVCLAGH-IJWZVTFUSA-N perfluorodecalin Chemical compound FC1(F)C(F)(F)C(F)(F)C(F)(F)[C@@]2(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)[C@@]21F UWEYRJFJVCLAGH-IJWZVTFUSA-N 0.000 description 4
- TXEYQDLBPFQVAA-UHFFFAOYSA-N tetrafluoromethane Chemical class FC(F)(F)F TXEYQDLBPFQVAA-UHFFFAOYSA-N 0.000 description 4
- QZCJOXAIQXPLNS-UHFFFAOYSA-N 1,1,2,2,3,3,4,4,4a,5,5,6,6,7,7,8,8,8a-octadecafluoronaphthalene 4-(2-aminoethyl)benzene-1,2-diol Chemical compound NCCc1ccc(O)c(O)c1.FC1(F)C(F)(F)C(F)(F)C2(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C2(F)C1(F)F QZCJOXAIQXPLNS-UHFFFAOYSA-N 0.000 description 3
- BOEIBTHDYSPVLT-UHFFFAOYSA-N 1,1-dichloro-1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-hexadecafluorooctane Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(Cl)Cl BOEIBTHDYSPVLT-UHFFFAOYSA-N 0.000 description 3
- 201000006474 Brain Ischemia Diseases 0.000 description 3
- 206010008120 Cerebral ischaemia Diseases 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 3
- 244000269722 Thea sinensis Species 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 125000001246 bromo group Chemical group Br* 0.000 description 3
- 206010008118 cerebral infarction Diseases 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 229940124447 delivery agent Drugs 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000007791 liquid phase Substances 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 230000003204 osmotic effect Effects 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 238000002600 positron emission tomography Methods 0.000 description 3
- 230000002685 pulmonary effect Effects 0.000 description 3
- 229910052704 radon Inorganic materials 0.000 description 3
- SYUHGPGVQRZVTB-UHFFFAOYSA-N radon atom Chemical compound [Rn] SYUHGPGVQRZVTB-UHFFFAOYSA-N 0.000 description 3
- 239000013589 supplement Substances 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 3
- MEBONNVPKOBPEA-UHFFFAOYSA-N 1,1,2-trimethylcyclohexane Chemical compound CC1CCCCC1(C)C MEBONNVPKOBPEA-UHFFFAOYSA-N 0.000 description 2
- QEGNUYASOUJEHD-UHFFFAOYSA-N 1,1-dimethylcyclohexane Chemical compound CC1(C)CCCCC1 QEGNUYASOUJEHD-UHFFFAOYSA-N 0.000 description 2
- CHNXZWQGMQOGRK-UHFFFAOYSA-N 1-chloro-1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9,9-nonadecafluorononane Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)Cl CHNXZWQGMQOGRK-UHFFFAOYSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- KAKZBPTYRLMSJV-UHFFFAOYSA-N Butadiene Chemical compound C=CC=C KAKZBPTYRLMSJV-UHFFFAOYSA-N 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 239000002280 amphoteric surfactant Substances 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 2
- 150000001721 carbon Chemical group 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229920005556 chlorobutyl Polymers 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 239000012045 crude solution Substances 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 229920001971 elastomer Polymers 0.000 description 2
- 238000004945 emulsification Methods 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 150000002170 ethers Chemical class 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000010685 fatty oil Substances 0.000 description 2
- 238000004817 gas chromatography Methods 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- DCAYPVUWAIABOU-UHFFFAOYSA-N hexadecane Chemical compound CCCCCCCCCCCCCCCC DCAYPVUWAIABOU-UHFFFAOYSA-N 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- ZQBFAOFFOQMSGJ-UHFFFAOYSA-N hexafluorobenzene Chemical compound FC1=C(F)C(F)=C(F)C(F)=C1F ZQBFAOFFOQMSGJ-UHFFFAOYSA-N 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical group 0.000 description 2
- 229910000040 hydrogen fluoride Inorganic materials 0.000 description 2
- 239000011229 interlayer Substances 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- UAEPNZWRGJTJPN-UHFFFAOYSA-N methylcyclohexane Chemical compound CC1CCCCC1 UAEPNZWRGJTJPN-UHFFFAOYSA-N 0.000 description 2
- 239000002736 nonionic surfactant Substances 0.000 description 2
- 235000012149 noodles Nutrition 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- RVZRBWKZFJCCIB-UHFFFAOYSA-N perfluorotributylamine Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)N(C(F)(F)C(F)(F)C(F)(F)C(F)(F)F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F RVZRBWKZFJCCIB-UHFFFAOYSA-N 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 229920001983 poloxamer Polymers 0.000 description 2
- 229920001993 poloxamer 188 Polymers 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000036387 respiratory rate Effects 0.000 description 2
- 238000005096 rolling process Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- OBGZODCYKSYLOI-UHFFFAOYSA-N 1,1,1,3,3,5,5,5-octafluoro-2,2,4,4-tetrakis(trifluoromethyl)pentane Chemical compound FC(F)(F)C(C(F)(F)F)(C(F)(F)F)C(F)(F)C(C(F)(F)F)(C(F)(F)F)C(F)(F)F OBGZODCYKSYLOI-UHFFFAOYSA-N 0.000 description 1
- BOSAWIQFTJIYIS-UHFFFAOYSA-N 1,1,1-trichloro-2,2,2-trifluoroethane Chemical compound FC(F)(F)C(Cl)(Cl)Cl BOSAWIQFTJIYIS-UHFFFAOYSA-N 0.000 description 1
- CMBKOSTZCGEKQA-UHFFFAOYSA-N 1,1,2,2,3,3,4,5,6,7-decafluoroindene Chemical compound FC1=C(F)C(F)=C2C(F)(F)C(F)(F)C(F)(F)C2=C1F CMBKOSTZCGEKQA-UHFFFAOYSA-N 0.000 description 1
- ZRQXDCFMDRAOSA-UHFFFAOYSA-N 1,2,3,4,5,6,7,8,9,10-decafluoropyrene Chemical compound FC1=C(F)C(F)=C2C(F)=C(F)C3=C(F)C(F)=C(F)C4=C(F)C(F)=C1C2=C43 ZRQXDCFMDRAOSA-UHFFFAOYSA-N 0.000 description 1
- KPZGRMZPZLOPBS-UHFFFAOYSA-N 1,3-dichloro-2,2-bis(chloromethyl)propane Chemical compound ClCC(CCl)(CCl)CCl KPZGRMZPZLOPBS-UHFFFAOYSA-N 0.000 description 1
- FBUHIWMNUBFIJZ-ZORUMLJWSA-N 1-O-(alpha-D-galactopyranosyl)-N-[8-(4-fluorophenyl)octanoyl]phytosphingosine Chemical class C([C@@H]([C@H](O)[C@H](O)CCCCCCCCCCCCCC)NC(=O)CCCCCCCC=1C=CC(F)=CC=1)O[C@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O FBUHIWMNUBFIJZ-ZORUMLJWSA-N 0.000 description 1
- DZWMJKOIMKFXIJ-UHFFFAOYSA-N 1-[2-(2-chloroethoxy)ethoxy]butane Chemical compound CCCCOCCOCCCl DZWMJKOIMKFXIJ-UHFFFAOYSA-N 0.000 description 1
- TWBBNRRRQNNSJY-UHFFFAOYSA-N 1-[2-(2-chloroethoxy)ethoxy]hexane Chemical compound CCCCCCOCCOCCCl TWBBNRRRQNNSJY-UHFFFAOYSA-N 0.000 description 1
- DURPTKYDGMDSBL-UHFFFAOYSA-N 1-butoxybutane Chemical compound CCCCOCCCC DURPTKYDGMDSBL-UHFFFAOYSA-N 0.000 description 1
- PVBMXMKIKMJQRK-UHFFFAOYSA-N 1-chloro-4-(4-chlorobutoxy)butane Chemical compound ClCCCCOCCCCCl PVBMXMKIKMJQRK-UHFFFAOYSA-N 0.000 description 1
- HMWAWZONWWOUGB-UHFFFAOYSA-N 2,2,3,3,5,5,6,6-octafluoro-1,4-dioxane Chemical compound FC1(F)OC(F)(F)C(F)(F)OC1(F)F HMWAWZONWWOUGB-UHFFFAOYSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 241001070941 Castanea Species 0.000 description 1
- 235000014036 Castanea Nutrition 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- 101100289061 Drosophila melanogaster lili gene Proteins 0.000 description 1
- 206010061857 Fat necrosis Diseases 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 208000012766 Growth delay Diseases 0.000 description 1
- 208000032456 Hemorrhagic Shock Diseases 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 208000006552 Lewis Lung Carcinoma Diseases 0.000 description 1
- 101100298048 Mus musculus Pmp22 gene Proteins 0.000 description 1
- 101100247316 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) ras-1 gene Proteins 0.000 description 1
- 101150075070 PFD1 gene Proteins 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 229920001774 Perfluoroether Polymers 0.000 description 1
- 101150076031 RAS1 gene Proteins 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 101000852966 Rattus norvegicus Interleukin-1 receptor-like 1 Proteins 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 206010049771 Shock haemorrhagic Diseases 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 1
- 244000300264 Spinacia oleracea Species 0.000 description 1
- 235000009337 Spinacia oleracea Nutrition 0.000 description 1
- 108010023197 Streptokinase Proteins 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 241000270666 Testudines Species 0.000 description 1
- SYKNUAWMBRIEKB-UHFFFAOYSA-N [Cl].[Br] Chemical class [Cl].[Br] SYKNUAWMBRIEKB-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000007824 aliphatic compounds Chemical class 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000035565 breathing frequency Effects 0.000 description 1
- 102220346944 c.44T>G Human genes 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 239000003518 caustics Substances 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000000498 cooling water Substances 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000002542 deteriorative effect Effects 0.000 description 1
- 150000004985 diamines Chemical class 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- RCJVRSBWZCNNQT-UHFFFAOYSA-N dichloridooxygen Chemical class ClOCl RCJVRSBWZCNNQT-UHFFFAOYSA-N 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 229940105990 diglycerin Drugs 0.000 description 1
- GPLRAVKSCUXZTP-UHFFFAOYSA-N diglycerol Chemical compound OCC(O)COCC(O)CO GPLRAVKSCUXZTP-UHFFFAOYSA-N 0.000 description 1
- MQRJBSHKWOFOGF-UHFFFAOYSA-L disodium;carbonate;hydrate Chemical compound O.[Na+].[Na+].[O-]C([O-])=O MQRJBSHKWOFOGF-UHFFFAOYSA-L 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- FVIZARNDLVOMSU-UHFFFAOYSA-N ginsenoside K Natural products C1CC(C2(CCC3C(C)(C)C(O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O FVIZARNDLVOMSU-UHFFFAOYSA-N 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 230000003741 hair volume Effects 0.000 description 1
- 238000009775 high-speed stirring Methods 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 230000004199 lung function Effects 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 210000004914 menses Anatomy 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- XKGUKYPCHPHAJL-UHFFFAOYSA-N methanetetracarbonitrile Chemical class N#CC(C#N)(C#N)C#N XKGUKYPCHPHAJL-UHFFFAOYSA-N 0.000 description 1
- GYNNXHKOJHMOHS-UHFFFAOYSA-N methyl-cycloheptane Natural products CC1CCCCCC1 GYNNXHKOJHMOHS-UHFFFAOYSA-N 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000005065 mining Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- GVGCUCJTUSOZKP-UHFFFAOYSA-N nitrogen trifluoride Chemical compound FN(F)F GVGCUCJTUSOZKP-UHFFFAOYSA-N 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 150000002927 oxygen compounds Chemical class 0.000 description 1
- UJMWVICAENGCRF-UHFFFAOYSA-N oxygen difluoride Chemical compound FOF UJMWVICAENGCRF-UHFFFAOYSA-N 0.000 description 1
- 238000006213 oxygenation reaction Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 229960004624 perflexane Drugs 0.000 description 1
- 229950008618 perfluamine Drugs 0.000 description 1
- ZJIJAJXFLBMLCK-UHFFFAOYSA-N perfluorohexane Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F ZJIJAJXFLBMLCK-UHFFFAOYSA-N 0.000 description 1
- JAJLKEVKNDUJBG-UHFFFAOYSA-N perfluorotripropylamine Chemical compound FC(F)(F)C(F)(F)C(F)(F)N(C(F)(F)C(F)(F)C(F)(F)F)C(F)(F)C(F)(F)C(F)(F)F JAJLKEVKNDUJBG-UHFFFAOYSA-N 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 235000021395 porridge Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 230000010410 reperfusion Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 229940001593 sodium carbonate Drugs 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 229940076133 sodium carbonate monohydrate Drugs 0.000 description 1
- 239000011775 sodium fluoride Substances 0.000 description 1
- 235000013024 sodium fluoride Nutrition 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229910052712 strontium Inorganic materials 0.000 description 1
- CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 235000015961 tonic Nutrition 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 229960000716 tonics Drugs 0.000 description 1
- 238000002627 tracheal intubation Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 1
- 235000012141 vanillin Nutrition 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0026—Blood substitute; Oxygen transporting formulations; Plasma extender
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/10—Preservation of living parts
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/10—Preservation of living parts
- A01N1/12—Chemical aspects of preservation
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/10—Preservation of living parts
- A01N1/12—Chemical aspects of preservation
- A01N1/122—Preservation or perfusion media
- A01N1/125—Freeze protecting agents, e.g. cryoprotectants or osmolarity regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/02—Halogenated hydrocarbons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/08—Ethers or acetals acyclic, e.g. paraformaldehyde
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/1806—Suspensions, emulsions, colloids, dispersions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C43/00—Ethers; Compounds having groups, groups or groups
- C07C43/02—Ethers
- C07C43/03—Ethers having all ether-oxygen atoms bound to acyclic carbon atoms
- C07C43/04—Saturated ethers
- C07C43/12—Saturated ethers containing halogen
- C07C43/123—Saturated ethers containing halogen both carbon chains are substituted by halogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C43/00—Ethers; Compounds having groups, groups or groups
- C07C43/02—Ethers
- C07C43/03—Ethers having all ether-oxygen atoms bound to acyclic carbon atoms
- C07C43/04—Saturated ethers
- C07C43/12—Saturated ethers containing halogen
- C07C43/126—Saturated ethers containing halogen having more than one ether bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C43/00—Ethers; Compounds having groups, groups or groups
- C07C43/30—Compounds having groups
- C07C43/313—Compounds having groups containing halogen
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Environmental Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Dentistry (AREA)
- Engineering & Computer Science (AREA)
- Radiology & Medical Imaging (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dispersion Chemistry (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Radiation-Therapy Devices (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
- Colloid Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
311 〇Si2100545號專利申請案 中文說明書修正頁(84年6¾ ) 1>7 五、發明説明( 琎明之枝術範圈 本發明有關含高度氟化,氯取代的,具7至9個碳原子之 非環狀有機化合物之姐合物* Μ及有闞製造及使用之方法 。更特別的,本發明有闞含此等高度氟化,氯取代的有機 化合物之乳化液。本發明亦有闞具有7至10個碳原子(Κ 7至9個碳原子)之非環狀過氟氯醚之乳化液。此等新穎乳 化液具有多種醫藥及输氧用途。其特別可作槩用照影劑供 各種生物影像形式用,如核磁共振、1SF -磁共振照像、超 音波、X-光、電腦斷層攝影及正子發射斷層攝影,作為 输氧劑或”人造血液"、用Μ治療心臟發作、中風及其他種 血管阻塞、作為冠動脈血管造形術之佐劑、及用於癌症放 射治療及化學療法。 發明之背長 高度氟化有機化合物,特別是全氟碳化合物,已熟知為 安定且化學鈍性。過去20年間已將許多注意力集中在此種 化合物於生物糸統之用途,因其能溶解並運送大量氧。此 等特性使其可作為照影劑、氧输送劑或”人造血液”、用於 治療心臟發作、中風、及其他血管阻塞,作為冠動脈血管 造形術之佐劑,及用於癌症放射治療及化學療法。 高度氟化有機化合物中,稱可用於此種用途中者為全氟 碳化合物,例如全氟萘烷、全氟茚滿、全氟三甲基贰環 [3, 3,1]壬烷、全氟甲基金鋼烷、全氟二甲基金網烷、及 全氟-2, 2,4,4-四甲基戊烷;9-1 2C全氟胺*例如,全氟三 丙胺、全氟三丁胺、全氟-1-氮雜三環胺;溴氟碳化合物 本紙張又度適用中國國家標準(CNS)A4規格(210 X 297公釐) -------------裝---------訂---\---Γ!線 (請先閲讀背面之注意事項再塡寫本頁) 經濟部中央標準局Β工消費合作杜印製 83.3.10,000 311(¾¾2100545號專利申請案 中文說明書修正頁(84年6饵) B7 五、發明説明(
X
經濟部t央標準局員工消費合作社印製 *例如,全氟辛基溴及全氟辛基二漠;F - 4 -甲基八氫喹嗪 及全氟醚*包括氛化多氟環醚。此種化合物揭述於*例如 ,美國專利案 3962439 , 3493581 , 4110474 * 4186253 , 4187252 , 4252827 , 4423077 , 4443480 * 4534978 , 4686024 , 4865836 , 4866096及 4868318 ,歐洲專利申請案 80716及158996,英國專利申請案1549038及German Of fen . 2650586 ° 靜脈内使用,高度氟化之有機化合物必須分散呈乳化液 。見,例如*L.C. Clark,(克拉克)Jr等人, "Emulsions of Perfluorinated Solvents for Intravascular Gas Transport," Fed. P r o c . . 34(6), 1468-77頁(1975); K 優可山(Yokohama)等人,"A Perfluorochemical Emulsion As An Oxygen Carrier, "Artif. Organs (CI eve) . 8(1),34-40頁(1984);及美 國專利案第4, 1 10,47 4及4, 1 87,252號。純的,高度氟化有 機化合物於血中不互混。 此種乳化液必不僅含足夠高濃度之高度氟化有機化合物 K有效運送所霈氧量*其亦必須能受滅菌(K熱較佳),在 流體或非'康結狀態有長安定性,能於血流中維持一段足夠 長時間以输送有用量之氧,且能足夠迅速自身體排除Μ避 免毒性及留滞於身體姐件及器官中。 發明夕餿詮 本發明有闞含高度氟化,經氛取代的,具有7至9個原子 之非環狀有機化合物之新穎姐合物,及製造及使用之方法 木紙張尺度適用中國國家標準(CNS) A4规格(21〇 X 297公釐) 83.3.10,000 ------------1裝---------訂!-——17’‘線 (請先閲讀背面之注意事項再塡寫本頁) 第S 2 1 Ο Ο 5 4 5號專利申請荼
中文說明書修正頁(84年6月)^ B7 修正 五、發明説明($) ~~ 補X 經濟部中央標準局負工消費合作社印裝 。更特別的,本發明有瞄新穎含高度氟化的,經氛取代有 機化合物之乳化液c 本發明之乳化液可用於各種運输氧之用途。其特別可用 於》學用途,例如,各種生物照像措施之照影基質,包括 核磁共振、超音波、19F -磁共振照相、X-光、霣腦斷層 攝影、及正子發射斷層攝影,作為氧输送劑或”人造血液 ”,用於治療心輟發作、中風、及其他血管阻塞、作為冠 動脈血管造形術之佐劑,及用於癌症放射及化學療法中。 圖之篛汰 圈1說明於输注後2,16, 30及60天存留於姐嫌中之全氟- 貳-氯丁基g(PFBCBE)之百分劑量; 其中 _1A為10¾ 2 0毫升/公斤劑量來自齧齒類肝之F -貳-氯丁 基醚乳化液之清除率。 圖1B為〗0及20毫升/·公斤劑最'來自齧齒類肺之F-贰-氛丁 基铤乳化液之清除率。 _1C為10及20毫升/公斤劑量來自齧齒類骨锤之F -贰-氛 丁基醚乳化液之清.除率。 HMD為10及20毫升/公斤劑量來自齧齒類脾之F-贰-氛丁 基醚乳化液之清除率。 發职夕茳拥銳明 為使更充份了解文中所述之本發明,敘述下列詳妞說明 本紙乐尺度適用中國國家螵率(CNS ) A4規格(.210X29?公釐) I 种衣 訂.iN (請先閱讀背面之注意事項再填寫本頁) „ β 第 δ 2 1 c31im 82100545號專利申請赛 A7 明書修正頁(84年6月)B7 五、發明説明(β) 太發明有翮各種离度氟化,經氯取代的有機化合物(”氛 氡化學物”)。此等化合物,特別是含彼等之乳化液,可用 於各種《蓁及氧運蝓用途。此高度氟化,經氯取代之本發 明化合物含7至9個碳原子,為非環狀,包括,例如,高度 氟化籯化學物,特別是氯全氟化學物,包括全氟氯醚、及 高度氟化的溴氯化學物,尤為溴氣全氟化學物。吾人較喜 全氟氛化學物。 本發明化合物一般共含三個氯或漠取代基,至少一個為 氛。Μ僅存在氯诹代基較佳。本發明化合物Μ具兩届氯取 (請先閱讀背面之注意事項再填寫本頁 裝 丁 、-»
-L 經濟部中央標準局員工消費合作社印装 本紙張尺度適用中國國家標準(CNS )六4規格(210X 297公釐) 311091 Α6 Β6 經濟部中央標準局員工消費合作社印製 五、發明説明(4 ) 代基更佳。 雖然氛及溴取代基理論上可位於化合物中任何碳原子上 ,吾人較喜當有超過一個此種取代基,其於不同碳原子上 時(即,非雙)。本發明最佳的氯氟化學物中- -1,8全氟二 氯辛烷--氯取代基位於碳鏈之相反端。合成本化合物之一 條途經述於A.Y.沙配代洛(Zapevalov)等人,"Synthesis And Reactions of Oxygen-Containing Organofluorine Compounds VI. Po1yf1uorinated Ketones With A Trifluoromethyl Group" , -lournal of Organic Chemistry nf t. h USSR. 14, 239-242頁(7, 1978) 〇 本發明亦涵蓋含N-,0-及S高度氟化,烴氯取代的,具7 至9個碳原子之非環化有機化合物。例如,可用四级胺、 醚或砸。應了解,任何本發明之高度氟化,經氯取代之有 機化合物可一起混合,或與其他熟知的高度氟化有機化合 物混合,用於本發明之乳化液中。 本發明高度氯取代的有機化合物為具有7至9個碳原子之 非環狀,直或支鏈化合物,Μ經取代之脂族化合物較佳。 Μ具有8個碳原子之化合物較佳。Κ具有8個碳原子經二 氛取代的化合物,例如,全氟二氯辛烷及全氟甙-氯丁基 醚更佳。依據本發明最佳的化合物是1,8 -全氟二氛辛烷 ("PFDC0")。 此外,本發明亦涵蓋具有7至10個碳原子之全氟氛醚類 • Μ具有7至9個碳原子之全氟氯醚較佳。含於本發明範圍 内之全氟氯醚包拮:[(Μ-(ερ2:)4-〇-]2π?2, 本紙張尺度適用中國國家標準(CNS)甲4規格(210 X 297公货) (請先閲讀背面之注意事項再填寫本頁) i裝- 訂. 在· 311¾0¾1 〇0545號專利申請察 中文說明書修正頁(84年)
及 五、發明説明(f) [C 卜(CF2)3-〇-]2CFCF3, [n-C2P4-0-C2F4-0-]2CF2 (C4Fe-〇-)2〇FCF2-Cl, c5Fii-〇_CF(CF2'C1)2* [(ci-cf2)2cf-o-]2cf2, c4f9-〇-c(cf2-cd3, C1-CF2C(CF3)2CF2-0-(CF2)4-c1> C1-C2Fa-〇-CF(CF3)CF(CF3)-〇-C2F4'CK C8Fiv-0-CF2-C1, CbFh-0-(CF2)b-C1, CF3-〇-(CF2)a-Cl, C]-C2Fa-〇-<CF2)4"0'CzF4~C1, Cl-(CF2CF2-0-)3C2F4-Cl, (CF3)3C-0-(CF2)5-Cl, C4Fa-0-CF2CF(CF2-Cl)-0-CF3, C4F〇-0-C2F4-0-C2F4-C1, CeFi3-0-CzF4-0-C2F4-Cl 全氟貳氯丁基醚。較喜 c4pe-0_c2p4_0_c2p4_c:l’ CeF13-0-C2F<i-0-C2F4-Cl 及全氣-¾-氯丁基酸’以全氣-贰-氯丁基醚較佳。 氟化氯醚或氟氯醚先質Μ產生可用於本發明之全氟氛鍵 之方法有數種。此種先質,例如,贰氛丁基酸,丁氧基乙 氧基乙基氯及己氧基乙氧基乙基氯,可購得或可由本技藝 中之原有技術之一立即合成。 吾人較喜固相或液相直接氟化作用,如美國專利申請案 4,755,567、 4,859,747、 5,093,432,及公告的 PCT申請案 W0 90/06296中。氛醚或氟氯醚先質之直接氟化作用在適 中或接近四周溫度,例如,-20〇C至+50CC下,用化學計量 過量之氟氣進行。氟氣用鈍性氣體如氮稀釋較佳,κ使純 氟氣之傷害減至最少或避免,並K控制先質與氟初接觸時 產生熱之量。氟化作用可於無氧-及水-環境中進行,且可 ,裝 訂 I . I線 (請先閱讀背面之注意事項再填寫本頁) 經濟部_央標準局員工消費合作杜印製 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公梦) 83.3.10,000 A6 B6 經濟部中央標準局員工消費合作社印製 五、發明説明(6 ) 於固體粒子清除劑,例如,氟化納,之存在下進行,清除 所產生的氟化氫副產物。 吾人較喜於不存在氟化氫清除劑下使用液相直接氟化作 用。氟氛醚先質分散在鈍性液體中,如氟碳或氟氯碳液體 。反應於足K揮發氯化氫副產物並當產生時能使其自氟化 帶去除。見,例如,公告的PCT申請案W0 90/06296。 供靜脈内使用,本發明高度氟化,經氯取代的有機化合 物分散呈乳化液。此種乳化液可含高至約60X(K體積計) 之含氣化合物。本發明乳化液Μ含約10Χ至約50Χ (Μ體積 計)高度氟化,經氛取代之有機化合物較佳。乳化液含約 25¾至約40ΜΚ重量計)本發明之氯氟化學物最佳。 本發明之乳化液使用習用方式及方法製造,並包括熟知 的高度氟化有桷化合物之乳化液常用之姐份。用於本發明 乳液中之界面活性劑為任何已知的陰離子性、陽離子性、 非離子性及兩性游子性界面活性劑。較佳者為非離子性表 面活性劑如烷基或芳基化合物,其親水部份由聚氧乙烯鍵 ,糖分子,多酵衍生物或其他親水基因姐成,例如,商名 "普洛尼克(Pluronic)”之聚氧乙烯及聚氧丙烯氧化物之 BASF楊多特(Wyandotte)調配物,例如普洛尼克F-6 8或 F-108,或兩性游子性界面活性劑。氟化界面活性劑,例 如,ATSURF*® F-31 CICI, Wilmington, DE),亦可用於 本發明乳化液中。見,例如,利斯(Riess)等人, "Design, Synthesis and Evaluation of Fluorocarbons and Surfactants for In Vivo (請先閲讀背面之注意事項再場窝本頁) 丨裝_ 訂Ί 7.4· 本紙張尺度適用中國國家標準(CNS)甲4规格(210 X 297公釐) 經濟部中央標準局員工消费合作社印刺衣 A6 ____B6_ 五、發明説明(?)
Applications, New Perf 1 uoroa 1 ky 1 ated P〇 lyhydroxy lated Surfactants", A r t. i f . Cells
Ajt i f ._Qr-Kans.. 16,421-30 頁(1988)。再次,此等界面 活性劑之姐合當然可用於本發明之乳化液中。此外,化合 物之混合物,其中之一或多棰不是界面活性劑,但化合物 合併時作為界面活性劑,亦可用作本發明乳液之界面活性 劑姐份。 用於本發明乳化液中之界面活性劑為合生理性者較佳, 例如,下列之一或多種:蛋或大豆磷脂、蛋黃素、及油酸 之烷基鹽,如油酸納。Μ蛋黃素較佳。雖然用於本發明乳 化液中特定界面活性劑依據乳化液其他成份之數量及特性 而定,一般施用約0.5至105Κ(Κ全乳化液之重量計)界面活 性劑。使用約1至約4¾ (Μ重量計)更佳。 本發明之乳化液亦含有大致無表面活性且不具有意義水 溶性之油。此種油為•例如,述於EP 231,091, W0 89/10118及U.S. Pat. 4,866,096中者。包括液體脂肪油 、烴、石媸、如脂肪酸與單氫氧化醇之單酯、長鍵醚、二 酸甘油醅、三酸甘油酯、矽嗣油及腈類。此類中可用的油 為油酸棕櫊醯基酯、辛基睛、十二基睛、大豆油、紅花油 、礦油、十六烷、及具有(:12-18碳鐽之二酸甘油酯及三酸 甘油酯。當然可使三酸甘油酯混合物用脂肪酸姐成類似三 酸甘油酯之油。此等油可單獨使用或Μ多種姐成用於乳化 液及本發明之方法中。當乳化液欲作®用時,油或油姐合 物當然為合生理用者。就此方:面,吾人較喜合生理用之液 -9 - 本紙張尺度通用中國國家標準(CNS)甲4規格(210 X 297公釐) L---------------^--------^----Ί— ----Tlft (請先閲讀背面之注意事項再填寫本頁) 311091 A6 B6 五、發明説明(8 ) 體脂肪油,如大豆及紅花油。 若存在,本發明乳化液中之油量,可於廣範園漘度下改 變*依據乳化液之其他姐份的濃度及特性而定,主要依據 乳液中高度氟化,經氯取代之有機化合物姐份之特點而定 。供任何設定姐份產生合用乳化液之實際油濃度可如本發 明所教用製備各種油漘度乳液之簡單技術容易地測定。此 技術中,一般施用約0.5至2 0X W/VS;油或油混合物。Μ施 用約1至5 W/VS:較佳。 經濟部中央標準局W工消費合作社印製 (請先閲讀背面之注意事項再填寫本頁) •裝· .:-.4. 除了高度氟化,經氯取代的有機化合物、油、界面活性 劑及水外,本發明之乳化液亦含習用於”人造血”或血液代 用品,氧输送劑或照影劑。例如,依據本發明之乳化液通 常亦含等張劑,一般為糖,如葡萄糖、甘霣糖及果糖、甘 油,或其他多氫酵以調整乳化液之滲透壓至約血液之滲透 壓。亦可於滅菌後由緩衡液如氯化納、重碳酸納、氯化鎂 等等調整滲透性,Μ減少紅血球细胞傷害之可能性。例如 ,吾人一般用約1至2.5Χ(Μ乳化液之重量計)此類劑。但 是,同樣可使用其他量及其他滲透壓控制劑,例如•泰洛 得(Ty rode)溶液。此外,此等乳化液可與0.9«食鹽水、乳 酸化林格爾氏溶液,血淸及血清製品混合而對乳化液粒子 大小及安定性無不良作用。本發明之乳化液亦包括其他姐 份,如腫脹劑,例如,葡聚糖或羥基乙基-鸦粉(HE S),及 抗氧化劑。 本發明之最佳乳化液中,氯氟化學物是PFDC0 |界面活 化劑是卵黃蛋黃素,若存在油,是紅花油。一般加甘油至 本纸張尺度迺用中國國家標準(CNS)甲4規格(210 X 297公釐) 100545號專利申請案 中文說明書修正頁(84年6另) B7 五、發明説明( - 年月曰、 84· 6· -9 補无 經濟部令央標準局0工消費合作社印焚 乳化液以調整等張性。本發明之最佳乳化液中,存在 PFDCO約40SIM體積計,蛋黃素約2.0 W/VS;,若存在*約乳 化液之2.0 W/VS;。 如上所述,本發明之含高度氟化,經氯取代的化合物之 乳化液可作為照影劑。缺少氫,其於選擇的身體部份產生 信號空處,可由各種照相措施與相鄰身體部位區分,例如 、核磁共振、超音波、X-光、電腦斷層攝影及正子發射 斷層攝影。此外,本發明之化合物及其乳化液可作為照影 劑及於ieP-MRI中直接照相。 當作為照影基,本發明之乳化液可由例如,大量靜注、 口服、皮下、腹腔内、熥鞘内、及其他獲許可之投藥方法 投藥,例如,插管,至轧化液能夠產生所需部位或解剖片 的清析簡明之影像。 本發明之乳化液亦可作為人造血使用,靜脈輸注至罹患 失血或失氧血之動物或人類。因此,本發明之乳化液亦可 用K維持活物種或其細胞成份例如,细胞糸之氧需求。除 了供動物及人類之人造血用途外,此等乳化液可作為保存 體之灌流液,如器官移植物,供長時間存於艘外。 證明含高度氟化有機化合物之乳液保存器官於人類或動 物體外之用途之公開文件包括卡瓦木拉(Kawamura)等人, "A Hew Simple Two layer (Euro-Collins'
So1utίοn/Perf 1 uorochemica 1) Cold Storage Method For Pancreas Preservation", Transplantation Proc. . 21,第 1376-77 頁(1989);西吉爾(Segel)與英菩 -11 - ------------j裝----------訂丨————丨-Ί.-線 (請先閲讀背面之注意事項再塡寫本頁) 本紙張又度適用中國國家標準(CNS)A4規格C210 X 297公釐) 83.3.10,000 經濟部中央標準局員工消費合作社印製 A6 _B6_ 五、發明説明(10 ) 沙(Ensunsa), "Albumin Improves Stability And Longevity of Perfluorocheaica1-Perf used Hearts", . J Physiol · ,254, H1105-12頁(1988);西吉爾等人 » "Prolonged Support of Working Rabbit Hearts Using Flusol-43 Or Erythrocyte Media" » Am, J_, PhvsiQL, 252, H349-59頁(1987);西吉爾輿瑞丁 (Rendig), "Isolated Working Heart Perfusion Vith Perf luorocheeica1 Emulsion Fluosol-43”, Am. J. Physiol·, 242, H485-89頁(1982)。氯氟化合物與本發明 乳化液同樣有用。 高度氟化有機化合物钃帶氧的能力使得其當分散作為乳 化液時可用以增進癌放射治療及化學療法,用於冠氣球血 管造形術,及治療心臓發作,中風及其他血管阻塞。證明 此種乳化液增進癌放射治療及化學療法之公告文件包括泰 査(Teicher)及羅斯(Rose),” Oxygen-Carring Perfluorochemical Enu 1 s i on As An Adjuvant To Radiation Therapy In Mice”,Cancer Res»_, 44,第 4285-88頁(1984);泰査及羅斯,"Effects Of Dose And Scheduling On Growth Delay Of The Lewis Lung Carcinoma Produced B y The Perfluorochemical Emulsion, Fluosol-DAf, , I n t . J . Radiation Oncol q kx. Biol · Phn 12,第 1311-13 頁(1986);洛克威爾 (Rockwell)等人,** Reactions of Tumors And Norma 1 Tissues In Mice To Irradiation In The Presence -12 - 本紙張尺度適用中國國家標準(CNS)甲4规格(210 X 297公釐) .----------------1:--------^------.玎-------線 (請先閲讀背面之注意事項再場寫本頁) 經濟部中央標準局8工消費合作杜印製 311091 A6 _B6_ 五、發明説明(11 )
And Absence of A Perfluorochemical Enulsion", I n t . J. Radiation Oncology Biol, Phvs.. 1 2,第 1315-18頁(1986);泰査及羅斯· "Perfluorochemical Emulsions Can Increase Tumor Radiosensitivity", Science, 223,第 934-36頁(1984);泰査等人,"Effect of Various Oxygenation Conditions And F1 uoso 1 -DA On Cytotoxicity And Ant i tumor Activity of Bleomycin In Mice”,J. Ha 11 > Cancer Inst.· 8 0,第 599-603頁(1988)。氯氟化學物及本發明之乳化液同樣有 用。 證明含高度氟化有機化合物之乳化液以使冠氣球血管造 形術之不良作用減至最小之公告文件包括菲馬尼 (Virmani)等人,"Myocardial Protection By Perfluorochenical Infusion During Transient Ischemia Produced B y Balloon Coronary Occlusion·’, Am. Heart J. . 116,第 42 1 -3 1 頁(1 988);傑夫(Jaffe)等 A · "Preservation Of Left Ventricular Ejection Fraction During Percutaneous Transluminal Coronary Angioplasty By Distal Transcatheter Coronary Perfusion of Oxygenated Fluosol DA 20^* Am. Heart J.. 115,第 1156-64頁(1988);克萊門
(Cleman)等人;"Prevention of Ischemia During Percutaneous Transluminal Coronary Angioplasty By Transcatheter Infusion Of Oxygenated Fluosol DA -13 - 本紙張尺度適用中國國家標準(CNS)甲4規格(210 X 297公釐) ------------------------裝----— -訂------線 - . -泰 (請先閱讀背面之注意事項再塡寫本頁) A6 B6 五、發明説明(12 ) 20X",Circulation. 74,第 555 - 62頁(1 986 );安德森 (Anderson)等人•”Distal Coronary Artery Perfusion During Percutaneous Transluminal Coronary Angioplasty”* An . Heart J. ,110,第 720-26頁(1984)。 本發明之氛氟化學物及乳化液同樣有效。 證明含高度氟化有機化合物之乳化液治療心臓發作、中 風及血管阻塞用途之公告文包括皮爾雷斯(Peerless)等人 ,’'Modification of Cerebral Ischemia With Fluosol", Stroke. 16,第 38 - 43頁(1 985);歐斯特風 (Osterholm)等人,”Severe Cerebral Ischemia Treatment By Ventriculosubarachnoid Perfusion With An Oxygenated Fluorocarbon Emulsion’、 Neurosurg . · 13.第 381-87 頁(1983);皮爾斯等人; "Protective Effect of Fluosol-DA In Acute Cerebral Ischemia", Stroke. 12,第 558-63頁(1981); 弗曼(F o r b a η )等人;"R e d u c t i ο η 0 f I n f a r c t S i z e W i t h Intracoronary Perfluorochemical In A Canine Preparation of Reperfusion", Circulation· 71,第 1060-68頁(1985)。 經濟部中央標準局員工消費合作社印製 (請先閲讀背面之注意事項再塡寫本頁) 丨裝· ,4._ 本發明之乳化液可習由混合高度氟化姐份(不連績相)與 水(迪績)相及界面活性劑混合製備。另外.本發明之乳化 液可用水相與任何適當界面活性劑.及視需要而定’滲透 劑,鍰衝劑,若需要電解質,其他乳化劑,另外的抗-氧 化劑,等等加至水性分敗液中混合製備。然後此高度氟化 -14 - 本紙張尺度適用中國國家標準(CNS)甲4規格(21〇 X 297公釐)
31ί$9ϊ 00545號專利申請栗 中文說明書修正頁(84年6笮) Β7 五、發明説明(6) 姐份混合至水性分散液内Κ提供本發明之乳化液。 本發明之乳化液亦可預先將水性分散液與任何適當界面 活性劑及,視需要定,其他習用人造血成份,例如,滲透 劑等等。若存在油,然後以預定速率混合入上述水性分散 液。然後高度氟化組份Κ預定速度混合以提供本發明之乳 化液。 將所得之乳化液滅菌,以溫度超過115°C較佳,於約 121 更佳,包装,否則經處理供貯存K及使用。 混合,若需要預混,组份之乳化作用可利用任何習用混 合器,均化器及乳化器進行。例如,可施用漁人牌觸摸混 合器及微液化器或高林(Gaulin)均化器。製備本發明乳化 液時,吾人較喜使用鈍性大氣(例如,預防界面活性 劑及脂肪油(若存在時)退變*並使用溫度約45 °C至55°C。 為更充份了解本發明*下文利用實例提供依據本發明說 明製備及使用之較佳乳化液。 g例 乳化液之郸備(方法A ) 自Kabi Vitrum取得粉化,精煉的蛋黃之蛋黃素分散在 滅菌H2〇[米尼波® (Millipore)],於氮氣(N2)使用瓦林 TM(WaringTM)摻和器以高速分散2-3分鐘。在鈍氣下收集 如此分散的蛋黃素,貯存於4QC。所有如此製得之蛋黃素 在其製備之一週内使用。 蛋黃素分散液(18.00XK重量計)由剌烈手搖懸散*然後 -15 - -------------装---------訂--.I---線 (請先閲讀背面之注意事項再填寫本頁) 經濟部中央準局員工消費合作社印製 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) 83.3.10,000
經濟部令央標準局員工消費合作社印製 17.01公克部份轉送至250毫升内入貯池中*再次於氮氣, 此貯池供應一種微液化器TW均化器。然後,蛋黃素進一步 用81.85公克水及2.94公克甘油於起動均化器前稀釋。然 後起動均化器,壓力保持在約8000 psi,流速約350毫升 /分鐘,約2分鏟。於一《相鄰的入口 *低於入内貯池之高 度,儘可能接近均化器入口,慢慢將油(3.5 0J:)引入(1-2 分鐘)。通過相同的相鄰入口慢慢(6-10分鐘)將氛氟化學 物(117.6公克,70.0毫升)緩緩添加(6-10分鐘)。均化物 通過均化器門瓣再循環15分鐘。控制添加0.47M Ma2C〇3或 其他鹼將PH保持在約8.5或更高。所得乳化液,含1.75 W/VSK蛋黃素、2.0 V/V!t^,及40.0 V/V5K氛氟化學物,於 旋轉蒸汽壓熱器中,於約121QC滅菌約15分鐘。
頌,化液之製備(方法FM 一夸脫瓦林(War ing)摻和器首先載装適當滅菌水 (137.0公克)、甘油(4.09公克)、蛋黃素(5.07公克)、界 面活性劑(5.02公克)、及氛氟化學物質(177· 05公克, 98. 910a充)刈Μ姐寒速混合2-3分鐘。然後將整個内容物 加至微液化器ΤΜ0: : 6器中之250毫升入内貯池内。起動均 化器,壓力保持在約8000 psi,流速約350毫升/分鐘。控 制添加0.47 M Ha2C〇3或其他鹼將PH保持在約8.0玆1郡高 。物質通過均化器循環約15分鐘。較大批之狀況(7500毫 升),乳化液可另於兩個不同之瓶中循環缌共6次。所得之 轧化液,含1.24 W/VX甘油,2.01 W/VS;蛋黃素,1.99 W/VX界面活性劑及38.23 V/VSK氛氟化學物,然後於旋轉的 -16- 本紙張尺度適用中國國家標準(CNS) A4規格(210 X 2刃公釐) 83.3.10,000 ------------^裝---------訂i——;「線 (請先閲讀背面之注意事項再填寫本頁) 第82100 5 45號專利申請荼 中文說明書修正頁(84年6饵) H 6· - 9 你、 B7 车El π fe*丄 五、發明説明(丨《) 補充 經濟部4-央標準局員工消費合作社印製 蒸氣懕熱器中,於約121°C,滅菌約15分鐘。 乳化菠之製備(方法Π ) 水(約3000.0公克)置於装有一個高速攪拌棒,氮人口, 及固體添加入口的5公升瓶内。起動攪拌器*加約2 7 0.70 公克蛋黃素及約257 . 7公克油至瓶内,保持在氮氣氛下。 於約1800 rpn繼續混合約15分鐘。此時*成份形成一種粗 乳化液。此粗乳化液送至一個装有低速攪拌器,氮入口, 水冷卻夾層及進料線之14公升瓶。輕度振搖,加約 4139.80公克水,接著加5»;碳酸納水溶液(約56.6公克)。 設定高林(Gaulin)M15R均化器門瓣至搡作壓約7500-9000 psi,粗糙乳化液通過此門瓣再循環,同時在均化器門瓣 前Μ速度約15公克/分鐘加91 04.90公克氛氟化學物至混合 物内。氯氟化學物添加完全後,全部乳化液循環至另一個 14公升瓶(裝備與第一個相同)内,在前述門瓣至約 7500-9000 Psi下繼績均化。均化物通過均化瓣約10次, 各次通至另一個瓶中。此時,施用冷卻水至瓶夾層使均化 物之溫度保持在約30QC (門瓣之入口側)及53°C (門瓣之出 口側)。收集乳化液*裝瓶至350毫升容器内,於1210C, 於裝有旋轉籃之壓熱器中滅菌15分鐘。 上述方法中,用於製備下列舉例乳化液之特定方法示於 刮强内。實例1-9及11中,Μ小量於微液化器中*壓力約 7000及9000 psig,10至15分鐘,製備氯氟化學物乳化液 。賁例10大量於高林均化器中製備。水相之姐份,一般約 佔此等乳化液體積之60¾,未顯示出。 -17 - ------------f 裝---------訂丨丨:----J 線 (請先閲讀背面之注意事項再塡寫本頁) 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) 83.3.10,000 A6 B6 五、發明説明(16 ) 乳化液 窗例 1 DBF02-7R ίΡΡΓΝ)βΓΑΐ 成份 v / vX 滅Μ後 V / V% ν/ν% 蛋黃素 1.35 1.77 1.77 紅花油 1.61 1.99 2.16 甘油 1.23 1.61 1.28 PCFN 53.73 70.54 39.41 pH 0 s m b V i s c c PSD 滅菌前 9.02 308 5.66 260 滅菌後 8.24 311 7.41 267 a全氟氯壬烷 b滲透性(毫滲透壓) c於37°C之黏度(厘托) d由雷射光敢射器測得之粒子大小分佈平均值(毫微米) '--------------J--------裝------訂』-----^ (請先閲讀背面之注意事項再塡寫本頁) 經濟部中央標準局S工消費合作社印制农 -18 - 本紙張尺度適用中國國家標準(CNS)甲4規格(210 X 297公釐) 311091 A6 B6 五、發明説明(17) 窖例 2 乳化液 DRF2-7R (PFCn)B [A] 滅菌後 成份 M / Μ% W / V劣 v/vS! 蛋黃素 1.36 1 . 79 1.79 紅花油 1.54 2 . 02 2.20 甘油 1.23 1.62 1.28 PFC0 53.87 70.79 39.55 pH 0 s m V i s c PSD 滅菌前 8.86 314 7 .78 251 滅菌後 8.25 314 6 .85 309 a全氟氯壬烷 -----------------V--------裝----.1—訂·---— η 線 (請先閲讀背面之注意事項再填寫本頁) 經濟部中央標準局S工消費合作社印製 -19 - 本紙張尺度通用中國國家標準(CNS)甲4規格(210 X 297公釐) A6 B6 五、發明説明(18 ) 乳化液 R A S 6 -5 4 (PFnnn)a [B] 滅菌後 成份 Μ / M% M / W% ν/ν% 蛋黃素 1.53 2.02 2.02 紅花油 1.51 1.99 2.16 甘油 1.30 1.71 1.35 PFDC0 53.82 70.72 39.51 pH 0 S D Vise PSD 滅菌前 8.85 3.34 9.22 187 滅菌後 8.58 3.27 7 . 98 199 a全氟二氯辛烷(1,8-全氟二氯辛烷) --------------1--------裝------.玎----1:線 (請先閲讀背面之注意事項再填寫本頁) 經濟部中央標準局R工消費合作社印製 -20 - 本紙張尺度適用中國國家標準(CMS)甲4规格(210 X 297公釐) A6 B6 五、發明説明(19 ) g例 4 a. 4h m R A S B - 5 R ( P F I) Π Π )「R 1 (請先閲讀背面之注意事項再塡寫本頁) _裝· 滅菌後 成份 Μ / V% W / V尨 v/vS! 蛋黃素 1.53 2.01 2.01 紅花油 1.47 1.93 2.10 甘油 1.23 1 . 62 1.28 PFDC0# 53.98 70.79 39.65 =!=包括異構物 pH 0 s m Vise PSD 滅菌前 8.80 2.83 6.05 187 滅菌後 8.35 2.78 5.93 196 經濟部中央標準局員工消費合作社印製 管例 5 乳仆液 r ASfl-i 2 f PFnnm [b] M菌後 成份 w/w$ v/v% w / v % 蛋 黃素 3.04 3.98 4. 33 紅 花油 0.00 0.00 0.00 甘 油 1.23 1.61 1 . 28 -21 - 本紙張尺度適用中國國家標準(CNS)甲4规格(210 X 297公釐) 31:1¾¾ϊ00545號專利申請案 中文說明書修正頁(84年6g 五、發明説明(W) a 補充 PFDC0 53.64 70.26 39 . 25 pH 0 s m V i s c PSD 滅菌前 8.69 330 7 .33 174 滅菌後 8.20 336 7 .46 213 啻例 fi % m RAS9-14 (PFnr.n) fRT m.m m 成份 w / w S! w/vis v/ V % 蛋黃素 0.38 .50 55 紅花油 0.00 0.00 0 . 00 甘油 1 . 25 1.65 1 . 31 PFDC0 53.86 70.87 39 . 59 | 裝 訂 « ^ I ^ 線 (請先閲讀背面之注意事項再塡寫衣頁) 經濟部令央標準局員工消費合作社印製 pH 0 s m Vise PSD 滅菌前 8 . 30 307 21 · 70 187 滅菌後 7 . 76 325 8.95 311 -22 - 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 29?公釐) 83.3.10,000 五、發明説明(21 ) A6 B6 筑,化液 當俐 7 RAS9-18 ηPFnnm 「ri 成份 V / V% 滅菌後 v/ V% v/v% 蛋黃素 1.51 1.97 1.97 紅花油 1.50 1.97 2.14 甘油 1.26 1.65 1.31 PFDC0 53.36 69.91 39.06 * 1,2全氟二氯辛烷 1包括異 構物 pH 0 s m Vise PSD 滅菌前 7.96 336 6.96 172 滅菌後 6.99 337 5 . 63 192 ---------------「,--------裝----;——·ΤΓ----- (請先閱讀背面之注意事項再塡寫本頁) 經濟部中央標準局員工消費合作社印製 -23 - 本紙張尺度適用中國國家標準(CNS)甲4規格(210 X 297公釐) A6 B6 五、發明説明(22) 啻例 8 乳化液 R AS 10-2 8 (PFnrn) [B] 滅蘭後 成份 V / V% V / V% V / V % 蛋黃素 0.38 0.05 0.50 普洛尼克F-68 (Pluronic F-68) 2.67 3.50 3.50 紅花油 0.00 0.00 0.00 甘油 1.24 1.64 1.30 PFDC0 54.19 71.32 39.84 pH 0 s m Vise PSD 滅菌前 8.59 314 17.70 201 滅菌後 8.23 322 9.35 345 官例 9 乳化液 ras 1 〇-.^〇 (PFnnn) [b] ---------------;---------裝------1#-----1 線 一 * ί (請先閲讀背面之注意事項再塡寫本頁) 經濟部中央標準局員工消費合作社印製 滅®甾 成份 w / w % W / V % v/v% 蛋黃累 2.56 3.50 3.50 -2 4 - 本紙張尺度適用中國國家標準(CNS)甲4規格(210 X 297公釐) 311091 A6 B6 五、發明説明(23) 紅花油 0.00 0 . 00 0 . 00 甘油 1.29 1.69 1.34 PFDC0 53.59 70.36 39.31 pH 0 s m Vise PSD 滅菌前 8 . 95 327 6.81 202 滅菌後 8.42 333 8.45 227 管例 10 乳化液 R AS1 0-1 8 ( P F Π Γ. Π ^ [Β] -------------------------裝-------ΤΓ------線 - · * 一~ (請先閲讀背面之注意事項再塡寫本頁) 經濟部中央標準局3工消費合作社印製 pH 0 s m Vise PSD 滅菌前 8.65 % •V 260 滅菌後 7.86 $ •V 257 -25 - 滅菌後 成份 Μ / V% Μ / S% v/vS: 蛋黃素 1.61 2.09 2.09 紅花油 1.53 1 . 99 2.16 PFDC0 54.10 70.31 40.18 本紙張尺度適用中國國家標準(CNS)甲4規格(210 X 297公g·) 經濟部中央標準局W工消費合作社印製 A6 B6 五、發明説明(24 ) *於未含甘油之乳化液不計算 當例 11 令瘰氡擗 各乳化液(A-G)中蛋黃素•紅花油及全氟氯醚(PFCE)之 量相當於2.00士0.05»/乂!1!蛋黄素、2.〇〇±〇.〇5»?/¥»:紅花 油,及40 士 2 v/vS!PFCE。乳化液(A-G)中之全氟氯醚自氟 氯醚先質中用液相直接氟化作用。於12l〇C滅菌25分鐘之 前姐合物之pH值用5Si碳酸納單水合物之水溶液調整至7.5 r 至9.0。乳化物可再生且對熱滅菌安定。 /- 令m m m丨 仆物 iB] 厂- .乳ibi"… 蛋黃素 油 ν&2°°3·η20 Η2〇 PFCE * . .· .(g) -.(g) .(g) 一 -· . - --- (g) (g) A {RAS7-62)3 5.02 4· 94 4.08 - 0·Ό48 ::- .137.· 1 . 172.64 B (RAS9-4)3 ... 22.00 21.7 18.07 0.20 601.9 776.80 C (KAS9-6)3 7,01 6.97 5.85 0.097 - 191-1 242.55 D (RAS9-30)3 7.00 -6.94 5-*83 0.074 192.0 242.07 E (RAS9-44)3 16.98 16.81 14.26 0.19 463.4 589.94 F (RWF12-96)b 5-05 4.95 4.22 0.028 136.6 166.17 G -· — 4. (RWF12-98)C 5.46 5.36 4,47 0.033 147.80 186.03 pH 0 s η V i s c PSD 乳化液 A 滅菌前 8.69 313 8 .65 220 滅菌後 8.09 316 7 .98 236 -26- 本紙張尺度通用中國國家標準(CNS)甲4规格(210 X 297公货) _·---------------1--------裝----^-I.玎.^——β (請先閲讀背面之注意事項再填寫本頁) 311091 A6 B6 五、發明説明(25 ) 經濟部中央標準局員工消費合作社印製 乳化液 B 滅菌前 8.45 348 10.65 213 滅菌後 7.65 346 9.87 215 乳化液 C 滅菌前 8.85 339 9.02 201 滅菌後 8.33 334 8.13 216 乳化液 D 滅菌前 8.82 329 8.90 216 滅菌後 8.36 330 8.45 232 乳化液 E 滅菌前 8.71 342 11.3 245 滅菌後 8 . 03 343 10.9 266 乳化液 F 滅菌前 8.10 324 5.81 264 滅菌後 7.59 319 5.90 264 乳化液 G 滅菌前 8.28 327 7 . 50 266 滅菌後 7.77 320 7.31 273 -27 一 (請先閲讀背面之注意事項再填寫本頁) 本紙張尺度適用中國國家標準(CNS)甲4規格(210 X 297公釐) 311091 A6 B6 經濟部中央標準局8工消費合作社印製 五、發明説明(26 ) a 全氟-贰-氯丁基醚(PFBCBE)
Cl-C^Fe-O-C^Fe-Cl b C4 F β - 〇 _ C 2 F·» - 0 - C 2 F4 - C 1 c CeF13-〇-C2F4-〇-C2F4-Cl 為塑造於人類血液循環中之安定性,乳化液A, B及EM 1:1與5¾人類血清白蛋白溶液混合於乳酸化的林格爾氐 (Ringer's)溶液內。於本基質中,37°C培養4天後*平均 粒子大小分佈•實例A為289奄微米,實例B為265毫微米 ,實例E為263奄微米。在此等條件下乳化液同樣清楚地 安定。 啻例 12 乳化液C(實例11)M速度1奄升/分鐘靜脈输注入兩姐 200-250公克白色斯布格道威(albino Sprague Dawley)雄 鼠内,總劑量為10毫升/公斤(40隻動物)或20毫升/公斤 (20隻動物)。於输注後第2、16、30及60天殺死各姐1/4。 分析各動物之肝、肺、脾、及骨路測量全氟-甙-氯丁基醚 (PFBCBE)之清除率。在一個组嫌磨器(Tissuemizer)中磨 碎姐嫌,用有機溶劑萃取,例如,氛仿、四氛化碳或三氟 -三氯乙烷萃取,由氣體層析分析。 圖I說明於输注後各時間點四個器官中各存留的 PFBCBE之平均百分比劑量。於服用缌劑量1〇毫升/公斤 PPBCBE之老鼠,主要姐嫌清除:幾乎所有的全氟碳,於接受 -28 - 本紙張尺度適用中國國家標準(CNS)甲4規格(210 X 297公货) --------------- --------裝--------17---^--~ ^ (請先閲讀背面之注意事項再填寫本頁) A6 B6 五、發明說明(27 ) 20牽升/公斤PFBCBE之老鼠中顯見排除之過程。因此, PPBCBE乳化液Μ可接受之速度清除。 雖然前文揭述許多本發明之具體實例,其他具體實例亦 存在本發明之範圍内。因此,應了解,本發明之範圍欲由 申請専利範圍界定,而非由前文Β由實例展現的特定具體 實例界定。 ..--------------7--------裝------訂.--- (請先閲讀背面之注意事項再塡寫本頁) 經濟部中央標準局員工消费合作社印製 本紙張尺度適用中國國家標準(CNS)甲4规格(210 X 2耵公货)
311091 第八二一〇〇五四五號專利申請案 中文補充説明書(八十四年六月) 下列數據證實吾等以含7至9個碳原子及至少2個氣原子之非環狀全氟 氣化合物製成之乳液特別適用爲氧輸送劑。吾等所測試申請專利之全 氟化合物乳液可有效自體内清除,且相較於先前技藝之乳液具有降低~ 之毒性效果。 反之:,以已知全氟化合物製成之乳液經測試結果,無法有效自體内— 清除或具有毒性(例如:肺氣腫)’因此較不適用。例如已知全氟(三/ 甲基環己燒)謗發嚴重肺過度氣腫,爲灌流吾等之乳液或生理食鹽水之 5倍量。此外,灌流30天之期間,累積在老鼠肝中之已知全氟全氫菲量 實際上會增加。 乳液之製法 基本上依下文所述,採用傳統之混合過程,分別使用此等全氟化合 物製備乳液: ⑻由蛋黃卵嶙脂、蔡花油及.全氟化合物於水中、惰性大氣(N2)下,以 華菱(Waring)授拌器高速擾拌約2分鐘,製成粗乳液。粗乳液移至仍 於惰性大氣下,且裝設MICROFLUIDIZER™ #100型均質器之容器 中。此粗溶液經均質ϋ以350毫升/分鐘之流速,使用60 psig空氣壓 力驅動幫浦活塞,共循環約15分鐘。此全程均保持50°C以下之溫 度,pH則控制在約7.5至8.5之間。
SJY/82G.DOCVWA ⑹依⑻項製祕紐,錢氣下私職細_瓶+,以鐵弗龍 襯歡J基橡膠隔片及錢密封瓶子。裝瓶後之乳液加熱殺菌,細 於旋轉殺菌器巾’以水賦加熱簡12m$15分鐘。 特定乳液之組成示於下表J 〇 PFC* (40體積%、 二氣化PFCs 表1.乳液 油 iw/v % ) 卵磷脂 (w/v % ) 螫 ·*· 1,9-全氟二氣壬烷(pfdCN) 2 2 . -.τκτ*· 1,8-全氟二氣辛烷(PFDCO) 2 2 1,2-全氟二氪辛烷(PFDCO) 2 2 —全氟(三甲基環己烷)(PFTMCH) 2 2 全氟全氫菲(35體積% PFC) 2 2 分析法 .i*- 爲了比較所製成乳液之特妹,在灌流30天後,分析氟化合物自老鼠 肝中清除之結果。吾等亦分析老鼠肺氣腫之程度,來決定乳液之毒 性。 I.自肝中清除之效果 ' 適用於生理上之氟化合物乳液必須可在血流中維持一段充份長時 間,以傳送有用之氧量。然而,氟化合物長期累積在肝組織中,會造 成肝臟脂肪壞死。因此氟化合物亦必須迅速自體内排出,以避免滞留 在體内及中毒。分析吾等所製成各押同乳麟含之氟化合物自奸中 清除之效果,方法如下: (a)爲史普勞-道利(sprague_Dawley)老鼠灌流包含4〇體積% pFDcN、认 PFDCO、1,2-PFDC0及PFTMCH之乳液(每隻1〇毫升/公斤),或包 含35體積%全氟全氫菲之乳液(每隻11.7毫升/公斤)。在灌流2天、 16天及30天後殺死老鼠。取出肝臟,於均質機中研磨,以含0.M% ' 正庚烷或正辛烷作爲内標準之四氣化碳萃取肝臟,以氣相層析法分 析肝'萃液,以分析肝中氟化合物含量。灌流16天或30天後之肝含量 以劑量%料示於圖P及表2中。亦由此數據計算半衰期㈣之天i,>' 示於表2。 ' 圖1中每長條均代表各老鼠之肝内殘留之全氟化合物劑量。劑量% 平均値示於長條圖上方。 **劑量%等於佔灌流至老鼠體内總pFC量之%。
SJY/82G.DOC/WA 311091 奉2 全氟化合物自老鼠肝中清除之效果 全氟化合物 肝中劑量% (灌流後天數) 2 1,8-PFDCO 51.23 1,2-PFDCO 49.91 1,9-PFDCN 58.61 全氟全氫菲 (35體積% PFC) 30.52 16 30 t%天數 12.17 6.8 6.43 4.7 38.65 46.6 53.63 〇〇
SJY/82G.DOC/WA 50.00 τ 劑 60.00 30.00 量 4400 >ΐοο % ^.00 10.00 0.00 全氟全氫菲 55ό3
-ririirtB %天
〇0.00 劑 50-00.- 40.00.. 量 30.00-· % 20.CO .. 10.00-· 〇.〇〇- — 60.00 y 劑 50.00 40.00 -- 量 3 争 00- % 香》- 10.00 * 0.00 -U 70.00 丁 劑 00.00 - 30.00 ” 量 40.00 -- 30.00 “ % 20.00 " 10.00 -· 0.00 ί 49.91
1,2-全氟二氯辛燒 16天 5:^3 1,8-全氟二氣辛燒》
1,9-全氟二氣壬烷 33.01 38.65
30天 天
SJY/S2G.DOC/WA
31109J π.肺氣麗 肺亂腫爲氟化合物之毒性現象之。這種氟化合物?丨起之肺氣腫嚴 重限制其於血液替代物及其他醫學上適用之組合物中之用途。不會引 走^員著肺氣腫之氟化合物乳液之毒性較低,因此較適合靜脈内使用。 吾等分析吾等以l,8_PFDC〇、12_PFDC〇及pFDCNK製成各種乳液 所誘發之肺氣腫量,方法如下: ⑻以礼液(10隻老鼠,各20毫升/公斤)或等體積之等張性生理食鹽水 灌流.史普勞-道利老鼠。4天後殺死老鼠。於量筒中測量肺部排水量-來決定肺體積。數據示於表3。 C.克拉克(Clark)等人’ ”以F-茶烷爲主之氟碳化物乳液之生理評估 及兔子之肺氣腫(Physi〇l〇gjeai evajua^jQn # with notes on F-decaline and pulmonary inflation in the rabbit) j Mater. Rgs. Soc. Symp. Proc., Volume Date 1987, 110 (Biomed, Mater,
Devices ) , pp. 129 -134,134,(1988)。 表3.全氟碳.化物對老鼠肺體積之影響 試驗化合物 體積(毫升/100克) 生理食鹽水 0.87 1,8-PFDCO 0.91 1,2-PFDCO 0.95 1,9-PFDCN 0.85 PFTMCH 4.87 SJY/82G.DOC/WA -6- 311091 結果 ι.自老鼠肝中清除 全氟全氫菲無法自財有效雜。灌流30天後,經觀之老鼠肝中
檢測到此全氟化合物5〇%劑量以上。反之,以1SL氯辛燒及U 全氟二氯核製蚊乳财有效自肝情除,1δ天後於肝巾之殘留量 已低於1W (圖1):以以全氟二氣壬垸製成之乳液亦比全氟全氯菲更. 有效地自肝中清除。灌流2天後,肝中發現58⑽劑量之1,9_卿CN。 PFDCN持續随時間自肝中清除,因此灌流%天後,肝中pFDc敗殘留 量僅爲38.65%劑量。 II.肺氣腫 以經至少2個氣原子取代之全氟化合物(如:18_pFDC〇,!,2棚 及PFDCN)製備之乳液所謗發之肺氣腫量(分別爲〇91毫升/⑽克, 0.95¾升/100克及〇.85毫升/则克)與生理食鹽水灌流後所謗發之氣 腫娜別讀/觸克)沒有骑上之差異。反之,PFTMCH誘發顯著 工肺風腫’即4.87毫升/卿克,爲生理食寧水灌流後所誘發肺氣腫之 至少5倍量。 · ♦ ,‘ 結論重點 本文所數據及吾等先前之説明中所示之數據證實吾等以含有7-9 個碳原子及至少2個氣之非環狀全氟化合物製備之乳液優於先前技藝之 乳液。 吾等工乳液可自肝中有效清除,不會使老鼠謗發顯著肺氣腫。參見 下列,纟示合圖1之黃色部份。 反之,以非氣化PFCs(如:全氟辛烷(,,pF〇”)、全氟壬烷 (PFN )、全氟(二甲基環己燒)、全氟氫菲及全氟勤充(PFD))製成之 乳液謗發顯著之肺氣腫或無法有效自肝中清除,或二者。參見综合圖】 中粉紅色部份。 此外,吾等證實含2個氣而不含7_9個碳原之Ci〇pFC不適合製造吾等 之乳液,其在室溫下呈固體。參見综合圖j之紫色部份。 σ等亦從貫僅含1個氣但分別含8及9個c原子之二種砰c〇, PFCN)未具有吾等乳液之優越特性。參見综合圖j之藍色部份。非環狀 8C單氣化PFC會謗發顯著之肺氣腫。雖然非環狀%單氣化pFC不會謗 發肺氣腫,但會在肝中累積。 最後,吾等顯示以溴取代之PFC(含α以外之鹵素):全氟辛基溴 (PFOB) ’製備之乳液在老鼠及稀彿中均出現吾等乳液所沒有之顯著毒 性效果。凊比較综合圖1及2之黃色(吾等申請專利之乳液)及綠色(pF〇B) 部份。 在老鼠中,PFOB謗發顯著量肺氣腫。溴化全氟化合物乳液在狒狒中 甚至出現更顯著之毒性效果> 經PF0B灌流之狒狒在灌流6〇天期間,展 現大幅增加之呼吸速率及大幅減少之血小板數。4隻狒狒中僅3隻存活 超過60天。反之,經PFDCO乳液灌流之狒狒之呼吸速率則與灌流生理 食鹽水之狒狒沒有統計上之差異,僅呼吸速率在一個時間點短暫地升 高,随後即回復對照組之速率。PFDCO乳液所引起之血小板數降低程 度亦較低。且所有接受PFDCO灌流之拂狒在灌流後均存活超過6〇天。 SJY/B20.D0CAVA -8 - 综合圖1 毒性效果 肺氣腫 自肝中 清除程序 (毫升/100毫升) S/2 (天) 二氯化物
CaF1RCI? (1,8 PFDCO) 非環狀,(^ 0.91 是 6.8 CrF16CI2(1,2 PFDCO) 非環狀,c8 0.95 是 4.7 CgF18CI2(1,9 PFDCN) 非環狀,Cg 0.85 是 46.6 is" * ϋ非環狀 二;職麵、' 室溫下呈固體, 麵猶鱗參雜鐵嫁黎^^竣多繼泰 恐·资务 i歡'灸叛灸髮為资S終衫衫
%_毒。減於MPFDO)切輯錢高,血小减少及死亡率提高
sJV/82G.D〇cyWA 311091 ’生理食鹽水 c8f16ci2 (1,8-PFDCO) • · · ' ' ..... C8(^7Br (PFOB). : ^ .... ......... ·.. ; . . . .... . ..... ... -.' . ' , ' ' : ' ·:· 全氟化合物 19-32 議議_______ 19-32 (暫時至 ~50) 呼吸速率 對狒狒之毒性效果 260-380K .....丨 116K 76K 血小板數 · .... 之. .. ϊΐ:; 囊 CO 存活率 ¾命涵2 SJY/82G.DOC7WA -10- Μ. η 年f月 Γ修正 曰補充 第八二一〇〇五四五號專利申請案1 _ *· ' .— 中文補充説明書11(八十四年七月) 吾等以本申請專利之乳液之特性’其中含有具7_9個碳原子與至少2 個氯原子之非環狀之氣全氟化合物,與含有不在本申請專利範圍内之 其他氟化合物之乳液作一比較,特定言之,吾等比較組成如下之乳液 之生理作用: / 1' (1)全氣_二氯辛烷,C8Fi6C12,係二氣化C8氟化合物; 二 ⑵二氣化Ci〇氟化合物,C10F2〇Cl2' ' , ⑶非鹵化氟化合物,全氟辛烷,C8F!8全氟壬烷,C9F20,及全氟萘 烷,Cl〇F20 ; ' 飞4)备7_9個碳之單鹵化全氟化合物,特定言之C9F19CI及C8F17CI ;及 ⑸全氟辛基溴化物,係經溴而非經氣修飾之8碳氟%物。 *此化合物於室溫下呈固體,熔點高於45°C。 結論概要 本文所示之數據證實吾等> 含有7-9個碳原子及至少2個氣原子之非 — 環狀全氟氯化合物製成之乳液特別適合靜脈内使用。吾等所測試之二 氣全氟化合物容易製成乳液,可有效地自體内清除,且毒性效果較 低。 反之,Ci〇二氣化全氟碳化物則未形成合適之乳液,其在室溫下呈 固態,且熔點高於45°C。同樣地,單氣化化合物亦未形成合適之乳 液。全氟氣壬烷無法有效地自肝中清除,且全氟氣辛烷會造成肺過度
SJY/81G.D0C/WA 氣腫。此外、’經非鹵化全氟化合物系經氣以外之卣素,即溴,修飾之 全氟化合物亦比吾等申請專利之乳液具有更高毒性副作用,即呼吸速 率提高’血小板數下降及存活率低,,或自組織中清除效果差。此等效 果使之較吾等之乳液更不適合靜脈内使用。 乳液之製法 基本上依下文所述,採用傳統之混合過程,分別使用此等氟化合教^ 製備乳液。+ , Γ; ⑻由蛋黃印嶙脂、葵花油及全氟化合物於水中、惰性大氣^2)下> .1/1 華菱(Waring)攪拌器高速攪拌約2分鐘,製成粗乳液―。粗乳液移 於惰性大氣下,且裝設microfLuidizer™ #100型均質器之容器 中。此粗溶袭經均質器以350毫升/分鐘之流速,使用60 psig空氣壓 力輕動幫浦活塞,共循環約15分鏟ό此全程均保持5〇°C以下之溫 度,pH則控制在約7.5至8.5之間。 ⑸依⑻項製成乳液後,在氮氣下裝入100毫升〗型玻璃瓶中,以鐵弗龍 襯裡之J基橡膠隔片及鋁蓋密封瓶子。裝瓶後之乳液加熱殺菌,其後 於旋轉殺菌器中,以水蒸汽加熱至約12Γ(:約15分鐘。 特定乳液之組成示於下表1。 \ 表1.乳液 PFC* 油 卵磷脂 體積% (w/v % ) (w/v % ) 二氣化PFCs 全氟二氯癸烷(PFDCD)** - _
SJY/81G.DOC/WA 全氟二氣辛痪(PFDCO) 2,. .2 . -— ~ 單氣化PFCs 全氟氣壬烷(PFCN) 2 2 全氟氣辛烷(PFCO) 2 2 未取代之PFCs— 全氟萘煉(PFD) 2 2 " —-· - 全氟壬烷(PFN) 2 . 2 - 全氟辛烷(PFO) 〆 2 2 ^^ibPFC - 全氟辛基溴(PFOB) 2 2 S. 分析法 爲了比較所製成乳液之特枉,在灌流30天後,分析氟化合物自老鼠 —T-·、· 肝中清除之結果。吾等亦分析老鼠肺氣腫之程度及狒狒接受乳液灌流 後之呼吸速率、血小板數及存活率,來決定乳液之毒性。 *PFC-全氟化合物 **無法製備。此化合物於室溫下呈固態,熔點超過45Ό。
SJY/8IG.DOC/WA sU〇9l 之效果 — -'— 適用於生理上之氟化合物乳液必須可在血流中維持一段充份長時 門以傳送有用之氧量。然而,氟化合物亦必須儘快自體内排除,以 避免在體内留滞及產生毒性。吾等分析吾等所製成各種不同乳液所含 之氟化合物自肝中清除之效果,方法如下: ⑻以每種乳液灌流史普勞_道利(Sprague_Dawley)老鼠(每種乳液24隻, 每隻1〇毫升/公斤)。在灌流後數個間隔時間點各殺死8隻老鼠。取’ 出肝-臟,於均質機中研磨,以含0.1-1%正庚烷或正辛烷作爲内標I準 之四氯化解取賴,以氣減躲鱗料液,以轉財 合物含量。30天後肝中所含劑量;^數據示於圖1及表2。 *劑量% *等於括灌流至老氣體内之總PFC量之%
SJY/81G.DOC/WA -4- 表2-全氟化合物自老鼠肝中之清除程度
全氟化合物 PFN PFOB PFDCO c9f19ci 肝中劑量1 2 38,3% ** < 5%3 47,6% 圖1 :全氟壬烷及全氟二氣辛烷自-老鼠肝中消除程度
灌流後天數
SJY/81G.DOC/WA 1 灌流30天後 2 清除速率大致與PFDCO相同 3 60天後,肝中殘留量低於0.1%劑量 311091 II.肺氣腫 、 肺氣腫爲氟化合物之毒性現象之這種氣化合物引起之肺氣腫嚴 重限制其於血液替代物及其他醫學上適用之組合财之驗。不會弓丨 起顯著肺祕d化合物乳社雜贿,目雜適合靜脈内使用。 吾等命吾等所製成各雛液㈣發之職齡度,方法如下: ⑻以扎液(10隻老鼠’各20毫升/公斤)或等體積之等張性生理食鹽水 灌流史普勞-道利老鼠。4天後殺死老鼠。於量筒中測量肺部排水量i 來決定肺體積。數據示於表3。 κ ς% *L. C.克拉克(Clark)寺人’ ”以F-茶垸r爲主之氟碳化物乳液之生理評伯;一 及兔子之肺氣腫(Physiological evaluaticm of fluoiOcarbon emulsicms with notes on F-decaline and pulmonary inflation in the rabbit ) » Mater. Res. Soc. Symp. Proc., Volume Date 1987, 110 (Biomed, Mater,
Devices ) , pp. 129-134,134, (1988)。 表3.全氟竣化物對老鼠肺體積之影響 試驗化合物 體精f毫井/100克) PFD 2.5 ‘ PFCO 2.28 PFOB 1.05 PFDCO 0.91 生理食鹽水 0.87 SJY/81GX)OCVWA -6- 311091 III·動物毒性、:狒狒模式 氧化合物雜之其他縣躺如:啊轉、刻、絲及動物死亡 率等之改變。因此亦分析這三種特性,來評估所製成各種氣化合物乳 液之毒性。 以吾等之氟化合物乳液或生理食鹽水灌流狒狒(每種乳液或生理食鹽 水灌流4隻_)。測定_之呼吸速率、血小板數及⑼天時之存活 率’分析乳液之雜。灌流4-7天後,使用人工計算法測定血小板數。丨 圖2顯示在灌流60天期間之各不同時間點之狒狒呼吸速率。經生^^ 鹽水灌流之狒狒之呼吸速率爲19-32次/分鐘。 _ 圖2 :經PF0B、PFD及PFDC0處理之彿稀之呼·吸速率之比較 2 0 8 6 4 1 1 呼吸次數\分鐘
0 0 0.17 1 2
PFD 卞FOB PRD CO 21 30 60 灌流後天數
SJY/81G.DO〇yWA 311091 表4顯示⑴4-7天時之平均血小板數,及(2)灌流60天後之存活率。 表4,狒狒之PFD、PFOB及PFDCO之比較 試驗'化合物 存活率 血小板數 PFD 1/4 30K PFOB 3/4 76K PFDCO 4/4 116K 生理食鹽水* ... 4/4** 260-380K 結果 I.二氣化<38對二氯化c10全氟化合物<
C8Fi6Cl2(PFt)CO)對 Ci〇F2〇Cl2(Caporiccio ) 二氣化全氟化合物,C10F20CI2,係.由明尼蘇達州礦業製造公司 (Minnesota,Ming and Manufacturing Co_)合成及提供。此全氟氣化合物 於室溫下呈固態,且熔點超過45°C。由於正常人體溫爲約37。〇,因此 不能使用Ci〇F2〇Cl2來製備靜脈用之乳液。 反之,I,8-全氟二氣辛燒,.‘C^MdyiipFDGO,,)爲容易製成乳液之液 體。以PFDCO製備之乳液可有效自肝中清除_3〇天後之肝中殘留量低一〜 於5% (圖1),於60天時,偵測到約〇以(表2)*。 Π_二氣化對單氯化全氟1合物
CgFi 6Cl2(PFDCO)#C9Fi 8Cl(Wesseler )#C8F! 7C1 表2及3所示輯亦顯示以含有至少2個氣之全氟氣化合物(如: PFDCO)製成之乳液相較於以單取代之全驗化合物如·全氟氣壬燒
SJY/81G.DOC/WA (”PFCN”)C9F19C1及全氟氣辛燒ς ”PFCO”)C8f17C1製成之乳氣具 有更優越之肝清除特性或降低之肺 A. 自肝中清除 PFDCO可有效自肝中清除-在灌流3〇天後,肝中殘留之pFDC0劑量 低於5%,60天後,肝中檢測到之pFDc〇劑量爲約0.1% (表2)。單氣化 全氟氣壬烷無法有效自肝中清除。30天後,C9F19CI在肝中之殘留量~ 仍達劑量之47.6% (表2)。 ,. *吾等亦分析使用PFDCO之類似物,1、2-全氟二氣辛烷製成之乳液自肝—一" 中清除之效果。16天後,肝中ι,2-‘氟二氣辛燒劑量仍殘留6.43%。 B. 肺氣腫 比較PFDCO及PFCO乳液所誘發之肺氣腫量。表3之數棣顯示, PFCO乳液誘發相當高量肺氣腫,2.58毫升/100克,相較於PFDCO乳 液,爲0.91毫升/100克。PFCO乳液謗發相當高量肺氣腫之現象使之 不適用於靜脈内用途。反之,PFDCO乳液赞謗發之肺氣腫量則與生理 食鹽水所誘發之程度(0.87毫弁/100克)在統計上沒有顯著差異。 III.二氣化對無氣化全氟化合物 〜 C^l 6Cl2(PFDCO)對 C9F2〇(PFN)及Ci 〇F2〇(PFD) 以經至少2個氯取代之全氟化合物製成之乳液比以無氣化之全氟化合 物(如:全氟辛燒’ CgFisC’PFO’’),全氟壬烷,C9F2〇(,,PFN”)及全氟莕 烷’ Ci〇F2〇("PFD")製成之乳液更適合靜脈内使用。 A.自肝中清除
SIY/E1G.DOC/WA 311091 圖1所示數據顯示,PFN未迅速自.體内清除。灌流30天後,肝中PEN 劑量殘留38.3%。反之,30天後肝中檢測到之PFDCO劑量低於5%,60 天後,肝中殘留之PFDCO劑量約0.1% (表2)。 吾等無法測量鼠類肝中PFO之清除程度,因爲所有接受pf〇乳液灌 流之老鼠均在灌流約2天後死亡。檢視經PFO灌流之老鼠肺部時顯示有 嚴重肺過度氣腫。 B. 肺氣腫 ( ί 分析.以PFD或PFDCO製備之乳液所謗發肺氣腫量。表3之數據顯示全_ 氟秦規乳液顯著誘發更多肺氣腫量(2:5毫升/1〇〇克),高於pFDCO季[/ 液(0.91毫升/100克)及生理食鹽‘灌流液(0 87毫升/1〇〇克))之謗發 程度。這種肺就腫量增加之現象使得含全氟萘烷之乳液比吾等之溶液 較不適合供靜脈内使用。 C. 動物毒性
V 以全氟茶燒製成之乳液對狒狒有毒性。 ⑻全氟萘烷乳液使呼吸速率提高至100次<分鐘,相較於pFDC〇乳液 則僅55次/分鐘,灌流生运食鹽水之彿狒則爲丨^次/分鐘(圖2)。 此外,PFD組在60天實驗期中均出現呼吸次數增加之現象,而\ PFDCO組則僅在灌流7天;^暫時增加至55次/分鐘,其他時間點則 均與生理食鹽水對照組沒有差異。 (b)全氟審燒乳液嚴重抑_狒之到'板數,由生理食鹽水灌流之彿狒 U60-380K/微升下降至全敦茶燒灌流之拂狒之胤^微升⑽。 這種血小板數嚴重受㈣之㈣會造錢血及㈣血性休克而死
SJY/81GDOC/WA •10- 311091 亡。PFD。。灌流之狒狒之血小板數爲116K/微升,顯著高於全象茗 烷灌流之狒狒之30K/微升(表4)。 (c)最重要者,4隻接受全氟苯燒乳液灌流之狒狒中,只有丨隻存活6〇天 (表4)。反之,接受PFDCO乳液灌流之狒狒則均存活60天以上。 IV氣化對溴化全氟化合物 C8Fl6Cl2(PFDCO)對 C8F17Br(PFOB) : ~ 全氟辛基溴與PFDCO自體内清除之速度實質上相同。然而,氣取代( 之全氟.化合物乳液所謗發之肺氣腫程度低(犯7)毒性效應低(犯8),使^^ 驚人地優於溴取代全氟化合物乳液,更適合靜脈内使用” A.肺氣腫 ’ 以經至少2個氣原子取代之全氟化合物如:pFDC〇製成之乳液所謗 養之肺氣腫量低於由經其他_素,即溴取代之全氟化合物所製成乳液 讀發量H含全氟辛錢之乳麟老鼠,發巾度之肺氣腫, 1.05毫升/100克,相較於生理食鹽水謗發量則爲〇 87毫升克。 此肺就腫上(差異表示對狒狒肺功能之毒隹。pFDC〇所謗發肺氣腫量 爲0.91毫升/100克,與生理食鹽水誘發量〇 87毫升刀〇〇克沒有統計 上之差異(表3)。 〜 B.動物毒性 全氟辛基溴(PF0B )乳液對狒狒之毒性高於pFDC〇乳液。毒性係 由呼吸速率、血小板數及存活率來決定。 _嗎發呼吸鱗增加至119以錄,她於生理食财伽_32 次/分鐘’且前者在6〇天實驗_均未喊正常(κ2及表4)。經
SJY/81GDOC/WA 11 311091 PFDCO乳、液灌流之狒彿之呼吸速李從未超過分次/分鐘。僅在暮流 7天後’出現此溫和升高之數値。其他時間點,pFDc〇所謗發之呼 吸速率則均與生理食鹽水對照組沒有差異。 (b)PFOB乳液亦抑制狒狒之血小板數至76K/微升。此血小板數顯著低 於PFDCO乳液灌流之狒狒(I·/微升)(表$,且遠低於生理食鹽水 灌流之狒狒(260-380K/微升)。 — (c)PFOB與PFDCO乳液之毒性差異亦展現在狒狒之存活率上。所有經丨: PFDQO乳液灌流之狒狒均存活6〇天以上。然而4隻經PFOB乳液灌流 . 之狒狒中,僅有3隻存活6〇天以上(表4) SJY/81G.DOCVWA -12·
Claims (1)
- 第82100545¾專利申請案 中文申請專利範圍修正本(86年5月) A8 B8 C8 D8 --- β6. 5. 2 7 修正“ 8誠克 申請專利範圍 2 . 3 . 經濟部中央標準局員工消費合作社印製 5 . 6 . 一種作為氧输送劑之乳化液姐合物,其包含: 從1 3ί到60¾體積比之量的具有8或9個碳原子及2個氯 原子之非環狀氟氯烷或氟氯醚, 從0.1 S!到10¾重量比之量的生理可接受界面活性劑 ,其係選自蛋黃素、蛋及大豆磷脂、以及油酸之烷鹽姐 成之群, 以及非實質表面活性且非明顯溶於水之油,其係選自 紅花油及大豆油姐成之群。 —種作為氧输送劑之乳化液組洽物,其包含: 從1 S!到60¾體積比之量的具有8或9個碳原子及2個氯 原子之非環狀氟氯烷或氟氯醚, 從0.1 S:到10¾重量比之量的蛋黃素, K及非實質表面活性且非明顯溶於水之油*其係選自 紅花油及大豆油姐成之群。 根據申請專利範圍第1或2項之乳化液姐合物·其中氟 氛烷或氟氛醚以103!至50»!體積比之量存在。 根據申請專利範圍第1或2項之乳化液组合物,其中氟 氯烷或氟氯醚25¾至40Χ體積比之量存在。 根據申請專利範圍第1或2項之乳化液姐合物,其中非 環狀氟氛烷或氟氯醚具有8個碳原子。 根據申請專利範圍第1或2項之乳化液组合物,其中氟 氛烷是1 , 8-全氟二氛辛烷。 根據申請專利範圍第1或2項之乳化液组合物,其中氟 氯_是全氟氯醚。 本纸張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) (請先閱讀背面之注意事項再填寫本頁) Hl〇9i 六、申請專利範圍 3 第醚 圍 一—-範氯 利 專 請氟 申全 據為 根醚 雙 物 合 姐 液 化 乳 之 項 氯 氟 全 中 其 装— (請先閲讀背面之注意事項再填寫本頁) 訂 經濟部中央標準局員工消費合作社印製 2 本纸張尺度適用中國國家標準(CNS ) A4規格(210 X 297公釐)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/806,692 US5403575A (en) | 1991-12-12 | 1991-12-12 | Highly fluorinated, chloro-substituted organic compound-containing emulsions and methods of using them |
PCT/US1992/010736 WO1993011868A1 (en) | 1991-12-12 | 1992-12-11 | Highly fluorinated, chloro-substituted organic compound-containing emulsions and methods of making and using them |
Publications (1)
Publication Number | Publication Date |
---|---|
TW311091B true TW311091B (zh) | 1997-07-21 |
Family
ID=25194617
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW082100545A TW311091B (zh) | 1991-12-12 | 1993-01-29 |
Country Status (9)
Country | Link |
---|---|
US (2) | US5403575A (zh) |
EP (1) | EP0625068B1 (zh) |
JP (1) | JP3504264B2 (zh) |
AT (1) | ATE196857T1 (zh) |
AU (1) | AU665224B2 (zh) |
CA (1) | CA2125401C (zh) |
DE (1) | DE69231503T2 (zh) |
TW (1) | TW311091B (zh) |
WO (1) | WO1993011868A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10835603B2 (en) | 2018-06-01 | 2020-11-17 | National Tsing Hua University | Method for normalizing blood vessels of lesions by oxygen-loaded microbubbles and ultrasonic irradiation |
Families Citing this family (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6088613A (en) | 1989-12-22 | 2000-07-11 | Imarx Pharmaceutical Corp. | Method of magnetic resonance focused surgical and therapeutic ultrasound |
US5205290A (en) | 1991-04-05 | 1993-04-27 | Unger Evan C | Low density microspheres and their use as contrast agents for computed tomography |
MX9205298A (es) * | 1991-09-17 | 1993-05-01 | Steven Carl Quay | Medios gaseosos de contraste de ultrasonido y metodo para seleccionar gases para usarse como medios de contraste de ultrasonido |
US5403575A (en) * | 1991-12-12 | 1995-04-04 | Hemagen/Pfc | Highly fluorinated, chloro-substituted organic compound-containing emulsions and methods of using them |
US5420359A (en) * | 1992-12-11 | 1995-05-30 | Minnesota Mining And Manufacturing Company | Chlorofluoroether compositions and preparation thereof |
US5558855A (en) * | 1993-01-25 | 1996-09-24 | Sonus Pharmaceuticals | Phase shift colloids as ultrasound contrast agents |
IL108416A (en) | 1993-01-25 | 1998-10-30 | Sonus Pharma Inc | Colloids with phase difference as contrast ultrasound agents |
US5558853A (en) * | 1993-01-25 | 1996-09-24 | Sonus Pharmaceuticals | Phase shift colloids as ultrasound contrast agents |
US5658962A (en) * | 1994-05-20 | 1997-08-19 | Minnesota Mining And Manufacturing Company | Omega-hydrofluoroalkyl ethers, precursor carboxylic acids and derivatives thereof, and their preparation and application |
US5476974A (en) * | 1994-05-20 | 1995-12-19 | Minnesota Mining And Manufacturing Company | Omega-hydrofluoroalkyl ethers, precursor carboxylic acids and derivatives thereof, and their preparation and application |
US5840276A (en) * | 1996-01-11 | 1998-11-24 | Apfel Enterprises, Inc. | Activatable infusable dispersions containing drops of a superheated liquid for methods of therapy and diagnosis |
US5843024A (en) | 1996-05-17 | 1998-12-01 | Breonics, Inc. | Solution and process for resuscitation and preparation of ischemically damaged tissue |
US20050019266A1 (en) * | 1997-05-06 | 2005-01-27 | Unger Evan C. | Novel targeted compositions for diagnostic and therapeutic use |
US6221261B1 (en) | 1997-08-13 | 2001-04-24 | Edward E. Boss | Process for treating sewage using hydro fluoro ether polymers |
US6548047B1 (en) | 1997-09-15 | 2003-04-15 | Bristol-Myers Squibb Medical Imaging, Inc. | Thermal preactivation of gaseous precursor filled compositions |
US20010003580A1 (en) | 1998-01-14 | 2001-06-14 | Poh K. Hui | Preparation of a lipid blend and a phospholipid suspension containing the lipid blend |
US6302863B1 (en) * | 1998-06-16 | 2001-10-16 | Nikolai Tankovich | Method for removal of lipids via a perfluorocarbon tumescent solution |
US20010039952A1 (en) | 1998-11-10 | 2001-11-15 | Walter A. Hacker, Ph. D | Ultrasound enhanced chemotherapy |
CA2255413A1 (en) | 1998-12-11 | 2000-06-11 | Fracmaster Ltd. | Foamed nitrogen in liquid co2 for fracturing |
US6127430A (en) * | 1998-12-16 | 2000-10-03 | 3M Innovative Properties Company | Microemulsions containing water and hydrofluroethers |
US6159917A (en) * | 1998-12-16 | 2000-12-12 | 3M Innovative Properties Company | Dry cleaning compositions containing hydrofluoroether |
US6148634A (en) | 1999-04-26 | 2000-11-21 | 3M Innovative Properties Company | Multistage rapid product refrigeration apparatus and method |
US7220401B2 (en) * | 1999-09-24 | 2007-05-22 | Barnes-Jewish Hospital | Blood clot-targeted nanoparticles |
EP1306083A4 (en) * | 2000-07-20 | 2007-08-29 | Perftoran West Ltd | EMULSION OF PERFLUORIC ORGANIC COMPOUNDS USED FOR MEDICAL PURPOSES, METHOD OF MANUFACTURE AND METHODS OF TREATMENT AND PREVENTION OF DISEASES USING THE EMULSION |
US6676963B1 (en) * | 2000-10-27 | 2004-01-13 | Barnes-Jewish Hospital | Ligand-targeted emulsions carrying bioactive agents |
AU2003205144B2 (en) * | 2002-01-15 | 2008-09-04 | Board Of Regents, The University Of Texas System | Methods and compositions to reduce scattering of light during therapeutic and diagnostic imaging procedures |
NZ534500A (en) | 2002-01-24 | 2007-07-27 | Barnes Jewish Hospital | Nanoparticle-based emulsions specifically targeted to integrins |
US7170914B2 (en) * | 2003-06-27 | 2007-01-30 | Intel Corporation | Optical transmitters |
ES2491891T3 (es) * | 2004-01-16 | 2014-09-08 | Carnegie Mellon University | Marcaje celular para técnicas de resonancia magnética nuclear |
JP2008502726A (ja) | 2004-06-09 | 2008-01-31 | ケレオス インコーポレーティッド | キレートモノアミドの親油性誘導体 |
US20090117207A1 (en) * | 2005-11-29 | 2009-05-07 | Zoltani Csaba K | Methods and compositions for treatment of poison-caused pathology |
CA2649333C (en) * | 2006-04-14 | 2016-10-04 | Carnegie Mellon University | Cellular labeling and quantification for nuclear magnetic resonance techniques |
EP2012832A2 (en) * | 2006-04-14 | 2009-01-14 | Celsense, Inc. | Methods for assessing cell labeling |
EP2019667A4 (en) * | 2006-04-27 | 2012-08-22 | Barnes Jewish Hospital | DETECTION AND IMAGING OF TARGET TISSUE |
WO2008102065A1 (fr) * | 2007-02-14 | 2008-08-28 | Commissariat A L'energie Atomique | Emulsions fluorescentes pour l'imagerie optique |
US8227610B2 (en) * | 2007-07-10 | 2012-07-24 | Carnegie Mellon University | Compositions and methods for producing cellular labels for nuclear magnetic resonance techniques |
EP2209420A4 (en) | 2007-10-09 | 2014-01-22 | Univ St Louis | PARTICULARS FOR IMAGING |
US9468607B2 (en) | 2007-10-09 | 2016-10-18 | Washington University | Ligand directed toroidal nanoparticles for therapy and diagnostic imaging |
EP2280736B1 (en) * | 2008-05-02 | 2016-11-02 | Celsense Inc. | Compositions and methods for producing emulsions for nuclear magnetic resonance techniques and other applications |
FR2934953B1 (fr) | 2008-08-14 | 2011-01-21 | Commissariat Energie Atomique | Nanoemulsions de nanocristaux |
FR2934954B1 (fr) | 2008-08-14 | 2011-07-22 | Commissariat Energie Atomique | Emulsion fluorescente de vert d'indocyanine |
FR2934955B1 (fr) | 2008-08-14 | 2011-07-08 | Commissariat Energie Atomique | Encapsulation d'agents therapeutiques lipophiles ou amphiphiles dans des nanoemulsions |
JP2010254678A (ja) * | 2009-03-30 | 2010-11-11 | Fujifilm Corp | パーフルオロクロロエーテル溶媒を含有する液体組成物 |
US20100267842A1 (en) * | 2009-04-15 | 2010-10-21 | Richard Kiral | Emulsions of Perfluorocarbons |
US9808500B2 (en) | 2009-12-17 | 2017-11-07 | Washington University | Antithrombotic nanoparticle |
AU2010339809B2 (en) | 2009-12-17 | 2016-05-05 | The Washington University | Antithrombotic nanoparticle |
AU2011239414A1 (en) | 2010-04-15 | 2012-11-08 | The Washington University | Prodrug compositions, prodrug nanoparticles, and methods of use thereof |
FR2980365B1 (fr) | 2011-09-26 | 2016-02-12 | Guerbet Sa | Nanoemulsions, leur procede de preparation, et leur utilisation comme agent de contraste. |
FR2980364B1 (fr) | 2011-09-26 | 2018-08-31 | Guerbet | Nanoemulsions et leur utilisation comme agents de contraste |
US9095521B2 (en) | 2012-02-02 | 2015-08-04 | Washington University | Methods for improving muscle strength |
US10213448B2 (en) | 2016-03-25 | 2019-02-26 | Novazoi Theranostics | Ethanolamine-based lipid biosynthetic compounds, method of making and use thereof |
EP3508214A4 (en) | 2016-07-06 | 2020-05-13 | Chuo University | Therapeutic agent for ischemic diseases |
CN108125932A (zh) * | 2018-01-19 | 2018-06-08 | 中国药科大学 | 用于肺部递送药物增强肺部药物蓄积量的脂质纳米乳剂 |
US10814268B2 (en) | 2018-03-29 | 2020-10-27 | Samuel L. Shepherd | Process for separating gases from gas mixtures using hydro fluoro ether |
Family Cites Families (86)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2055083A (en) * | 1932-07-13 | 1936-09-22 | Winthrop Chem Co Inc | Pharmaceutical preparation |
US2490764A (en) * | 1945-07-04 | 1949-12-13 | Kinetic Chemicals Inc | Fluorinated organic compounds |
US3456024A (en) * | 1966-07-05 | 1969-07-15 | Dow Corning | Preparation of perfluoroalkyl halides |
US3435078A (en) * | 1967-05-16 | 1969-03-25 | Allied Chem | Alpha,omega-bis(fluoroperhaloisopropoxy) - perfluoroalkanes and process for preparing them |
GB1256162A (en) * | 1968-08-16 | 1971-12-08 | Braun Fa B | Improvements in and relating to liquid products for intravenous administration |
US3958014A (en) * | 1970-09-05 | 1976-05-18 | The Green Cross Corporation | Process for preparing injection-purpose fluorocarbon emulsion capable of carrying oxygen |
US3808090A (en) * | 1970-10-01 | 1974-04-30 | F Luhde | Mechanical abrasion of wood particles in the presence of water and in an inert gaseous atmosphere |
US3975512A (en) * | 1970-12-21 | 1976-08-17 | University Of Illinois Foundation | Non-toxic brominated perfluorocarbons radiopaque agents |
US3739033A (en) * | 1971-03-01 | 1973-06-12 | Allied Chem | Novel fluorinated aliphatic triethers |
US3823091A (en) * | 1971-05-19 | 1974-07-09 | Green Cross Corp | Stable emulsion of fluorocarbon particles |
US3942527A (en) * | 1972-03-14 | 1976-03-09 | Exxon Research & Engineering Co. | Blood oxygenation process |
US3778381A (en) * | 1972-04-24 | 1973-12-11 | Allied Chem | Fluorocarbon microemulsions |
US3914294A (en) * | 1972-06-01 | 1975-10-21 | Squibb & Sons Inc | 3,5-Disubstituted-2,4,6-triiodobenzoic acids |
NL7304074A (zh) * | 1973-01-23 | 1974-07-25 | ||
US3911138B1 (en) * | 1973-02-26 | 1996-10-29 | Childrens Hosp Medical Center | Artificial blood and method for supporting oxygen transport in animals |
US3993581A (en) * | 1973-10-05 | 1976-11-23 | The Green Cross Corporation | Process for preparing stable oxygen transferable emulsion |
JPS5331209B2 (zh) * | 1973-10-05 | 1978-09-01 | ||
FR2249657B1 (zh) * | 1973-11-07 | 1977-04-15 | Ugine Kuhlmann | |
JPS5126213A (ja) * | 1974-08-21 | 1976-03-04 | Tanabe Seiyaku Co | Johoseibiryushiseizaino seiho |
US4073879A (en) * | 1974-08-26 | 1978-02-14 | University Of Illinois Foundation | Brominated perfluorocarbon radiopaque agents |
US4073943A (en) * | 1974-09-11 | 1978-02-14 | Apoteksvarucentralen Vitrum Ab | Method of enhancing the administration of pharmalogically active agents |
US4104314A (en) * | 1976-07-14 | 1978-08-01 | Airco, Inc. | Ether compounds |
US4105798A (en) * | 1976-07-19 | 1978-08-08 | Sun Ventures, Inc. | Perfluoro polycyclic compounds for use as synthetic blood and perfusion media |
US4110474A (en) * | 1977-08-26 | 1978-08-29 | Suntech, Inc. | Tetramethylpentane blood substitutes |
US4186253A (en) * | 1978-10-10 | 1980-01-29 | The Green Cross Corporation | Perfusate for preserving organ to be transplanted and preserving method |
US4289499A (en) * | 1978-10-13 | 1981-09-15 | Childrens Hospital Medical Center | Selecting perfluorocarbon compounds for synthetic blood |
JPS55100312A (en) * | 1979-01-25 | 1980-07-31 | Toshiro Wada | Contrast medium for blood vessel |
US4252827A (en) * | 1979-05-23 | 1981-02-24 | The Green Cross Corporation | Oxygen-transferable fluorocarbon emulsion |
WO1981000002A1 (en) * | 1979-06-25 | 1981-01-08 | Suntech | Use of perfluorocarbon as burn treatment |
US4657532A (en) * | 1985-07-19 | 1987-04-14 | Thomas Jefferson University | Intra-peritoneal perfusion of oxygenated fluorocarbon |
CA1181011A (en) * | 1980-05-27 | 1985-01-15 | Robert P. Geyer | Perfluorinated n,n-dimethyl cyclohexylmethylamine and emulsions containing the same |
US4337211A (en) * | 1980-06-11 | 1982-06-29 | The Dow Chemical Company | Fluorocarbon ethers having substituted halogen site(s) and process to prepare |
FR2515198A1 (fr) * | 1981-10-22 | 1983-04-29 | Centre Nat Rech Scient | Microemulsions aqueuses de fluorocarbures indefiniment stables a une temperature donnee, procede d'obtention et application a titre de transporteurs d'oxygene |
US4569784A (en) * | 1980-11-17 | 1986-02-11 | Adamantech, Inc. | Preparation of a gel having gas transporting capability |
JPS5924132B2 (ja) * | 1980-12-02 | 1984-06-07 | 株式会社 林原生物化学研究所 | 栄養補給用乳剤の製法 |
US4395393A (en) * | 1981-08-10 | 1983-07-26 | Basf Wyandotte Corporation | Artificial blood emulsifiers |
JPS5832829A (ja) * | 1981-08-22 | 1983-02-25 | Green Cross Corp:The | 血管造影剤 |
CA1187882A (en) * | 1981-11-27 | 1985-05-28 | Kazumasa Yokoyama | Perfluoro compound and emulsion thereof |
US4599343A (en) * | 1981-11-27 | 1986-07-08 | The Green Cross Corporation | Perfluoroindolizines and emulsions thereof useful as blood substitutes |
JPS5892680A (ja) * | 1981-11-27 | 1983-06-02 | Green Cross Corp:The | パ−フルオロビシクロ化合物 |
US4591599A (en) * | 1981-11-27 | 1986-05-27 | The Green Cross Corporation | Perfluoropyrrolizines and emulsions thereof useful as blood substitutes |
JPS58170782A (ja) * | 1982-01-22 | 1983-10-07 | アイ・エス・シ−・ケミカルズ・リミテツド | 過弗素化複素環式化合物およびこれを含むエマルシヨン |
US4446154A (en) * | 1982-03-03 | 1984-05-01 | Thomas Jefferson University | Stroke treatment utilizing extravascular circulation of oxygenated synthetic nutrients to treat tissue hypoxic and ischemic disorders |
US4490351A (en) * | 1982-03-15 | 1984-12-25 | Children's Hospital Medical Center | Methods of treating disorders of an eye with liquid perfluorocarbons |
US4452818A (en) * | 1982-03-19 | 1984-06-05 | Haidt Sterling J | Extraocular method of treating the eye with liquid perfluorocarbons |
US4461717A (en) * | 1982-03-19 | 1984-07-24 | Sun Tech, Inc. | Stable gas-carrying compositions |
US4510335A (en) * | 1982-03-29 | 1985-04-09 | Lagow Richard J | Perfluorinated branched ether compounds |
US4443480A (en) * | 1982-04-12 | 1984-04-17 | Children's Hospital Medical Center | Artificial blood and other gas transport agents |
US4497829A (en) * | 1982-07-27 | 1985-02-05 | The University Of Pennsylvania | Process for preparing perfluorochemical emulsion artificial blood |
US4397870A (en) * | 1982-07-27 | 1983-08-09 | The University Of Pennsylvania | Process for prolonging retention of emulsion particles in the bloodstream |
US4423077A (en) * | 1982-07-27 | 1983-12-27 | The University Of Pennsylvania | Perfluorochemical emulsion artificial blood |
US4542147A (en) * | 1982-08-07 | 1985-09-17 | The Green Cross Corporation | Perfluoro-1-azatricyclic amine compound |
JPS5939870A (ja) * | 1982-08-30 | 1984-03-05 | Green Cross Corp:The | フルオロカ−ボン乳化製剤 |
JPS5946218A (ja) * | 1982-09-09 | 1984-03-15 | Green Cross Corp:The | フルオロカ−ボン乳化製剤 |
US4815466A (en) * | 1982-09-30 | 1989-03-28 | Perlin Alfred R | Surgical clip |
US4534978A (en) * | 1982-12-28 | 1985-08-13 | The Green Cross Corporation | Perfluorocycloamines |
WO1984003624A1 (en) * | 1983-03-17 | 1984-09-27 | University Patents Inc | Method for inhibiting the growth of anaerobes |
JPS59193814A (ja) * | 1983-04-20 | 1984-11-02 | Ajinomoto Co Inc | アミノ酸含有脂肪乳剤 |
CA1257828A (en) * | 1984-04-16 | 1989-07-25 | William Mccormick | Perfluoro compound dispersions containing reduced amounts of surfactant and process of preparation |
CA1257131A (en) * | 1984-07-27 | 1989-07-11 | John Y. Park | Total parenteral and enteral nutrition composition |
US4868318A (en) * | 1985-02-01 | 1989-09-19 | The Green Cross Corporation | Perfluoro chemicals and polyfluorinated compounds |
US4686024A (en) * | 1985-02-01 | 1987-08-11 | The Green Cross Corporation | Novel perfluoro chemicals and polyfluorinated compounds and process for production of the same |
IT1186704B (it) * | 1985-04-04 | 1987-12-16 | Motefluos Spa | Perfluorcalcani e aloperfluoroalcani,loro precursori e loro processo di sintesi |
SE8505048L (sv) * | 1985-10-25 | 1987-04-26 | Nutritional Int Res Inst | Nutritionsemulsion med syretransporterande egenskaper |
SE8505047L (sv) * | 1985-10-25 | 1987-04-26 | Nutritional Int Res Inst | Fettemulsion |
US4755567A (en) * | 1985-11-08 | 1988-07-05 | Exfluor Research Corporation | Perfluorination of ethers in the presence of hydrogen fluoride scavengers |
US5080885A (en) * | 1986-01-14 | 1992-01-14 | Alliance Pharmaceutical Corp. | Brominated perfluorocarbon emulsions for internal animal use for contrast enhancement and oxygen transport |
US5077036A (en) * | 1986-01-14 | 1991-12-31 | Alliance Pharmaceutical Corp. | Biocompatible stable fluorocarbon emulsions for contrast enhancement and oxygen transport comprising 40-125% wt./volume fluorocarbon combined with a phospholipid |
US4865836A (en) * | 1986-01-14 | 1989-09-12 | Fluoromed Pharmaceutical, Inc. | Brominated perfluorocarbon emulsions for internal animal use for contrast enhancement and oxygen transport |
IL82308A (en) * | 1986-06-26 | 1990-11-29 | Ausimont Spa | Microemulsions containing perfluoropolyethers |
DE3631561A1 (de) * | 1986-09-17 | 1988-03-31 | Hoechst Ag | Loesungen von fluorpolymeren und deren verwendung |
US4722904A (en) * | 1986-12-18 | 1988-02-02 | Fisher Scientific Company | Thermodynamically-stable aqueous perfluorocarbon microemulsion useful as blood gas control or calibrator |
US4895876A (en) * | 1987-03-20 | 1990-01-23 | Air Products And Chemicals, Inc. | Concentrated stable fluorochemical aqueous emulsions containing triglycerides |
US4866096A (en) * | 1987-03-20 | 1989-09-12 | Air Products And Chemicals, Inc. | Stable fluorochemical aqueous emulsions |
DE3720323A1 (de) * | 1987-06-19 | 1988-12-29 | Hoechst Ag | Verfahren zur herstellung von chlor, brom oder iod sowie ethersauerstoff enthaltenden, weitgehend perfluorierten alkylverbindungen und neue chlor, brom oder iod sowie ethersauerstoff enthaltende perfluoralkylverbindungen |
US5171755A (en) * | 1988-04-29 | 1992-12-15 | Hemagen/Pfc | Emulsions of highly fluorinated organic compounds |
US5053536A (en) * | 1988-09-28 | 1991-10-01 | Exfluor Research Corporation | Fluorination of acetals, ketals and orthoesters |
US5093432A (en) * | 1988-09-28 | 1992-03-03 | Exfluor Research Corporation | Liquid phase fluorination |
AU4524389A (en) * | 1988-09-28 | 1990-04-18 | Exfluor Research Corporation | Perfluoroacetal and perfluoroketal compounds and use thereof in thermal shock testing |
JP3069112B2 (ja) * | 1988-09-28 | 2000-07-24 | エクスフルアー・リサーチ・コーポレーシヨン | エポキシドの弗素化法 |
EP0609200A1 (en) * | 1988-12-02 | 1994-08-10 | Minnesota Mining And Manufacturing Company | Direct fluorination process for making perfluorinated organic substances |
US5114703A (en) * | 1989-05-30 | 1992-05-19 | Alliance Pharmaceutical Corp. | Percutaneous lymphography using particulate fluorocarbon emulsions |
US5116599A (en) * | 1989-07-31 | 1992-05-26 | Johns Hopkins Univ. | Perfluoro-t-butyl-containing compounds for use in fluorine-19 nmr and/or mri |
EP0440925A1 (en) * | 1989-12-13 | 1991-08-14 | The Green Cross Corporation | Internal organ-preserving liquid and method for preserving internal organs |
US5403575A (en) * | 1991-12-12 | 1995-04-04 | Hemagen/Pfc | Highly fluorinated, chloro-substituted organic compound-containing emulsions and methods of using them |
US5420359A (en) * | 1992-12-11 | 1995-05-30 | Minnesota Mining And Manufacturing Company | Chlorofluoroether compositions and preparation thereof |
-
1991
- 1991-12-12 US US07/806,692 patent/US5403575A/en not_active Expired - Lifetime
-
1992
- 1992-12-11 US US08/244,804 patent/US5785950A/en not_active Expired - Lifetime
- 1992-12-11 AU AU32484/93A patent/AU665224B2/en not_active Ceased
- 1992-12-11 DE DE69231503T patent/DE69231503T2/de not_active Expired - Fee Related
- 1992-12-11 CA CA002125401A patent/CA2125401C/en not_active Expired - Fee Related
- 1992-12-11 AT AT93900191T patent/ATE196857T1/de not_active IP Right Cessation
- 1992-12-11 EP EP93900191A patent/EP0625068B1/en not_active Expired - Lifetime
- 1992-12-11 WO PCT/US1992/010736 patent/WO1993011868A1/en active IP Right Grant
- 1992-12-11 JP JP51109493A patent/JP3504264B2/ja not_active Expired - Fee Related
-
1993
- 1993-01-29 TW TW082100545A patent/TW311091B/zh active
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10835603B2 (en) | 2018-06-01 | 2020-11-17 | National Tsing Hua University | Method for normalizing blood vessels of lesions by oxygen-loaded microbubbles and ultrasonic irradiation |
Also Published As
Publication number | Publication date |
---|---|
US5403575A (en) | 1995-04-04 |
WO1993011868A1 (en) | 1993-06-24 |
EP0625068A4 (en) | 1996-11-27 |
DE69231503T2 (de) | 2001-06-07 |
CA2125401A1 (en) | 1993-06-24 |
EP0625068B1 (en) | 2000-10-11 |
US5785950A (en) | 1998-07-28 |
ATE196857T1 (de) | 2000-10-15 |
JP3504264B2 (ja) | 2004-03-08 |
JPH07509397A (ja) | 1995-10-19 |
CA2125401C (en) | 2004-02-24 |
EP0625068A1 (en) | 1994-11-23 |
AU665224B2 (en) | 1995-12-21 |
AU3248493A (en) | 1993-07-19 |
DE69231503D1 (de) | 2000-11-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TW311091B (zh) | ||
TW577752B (en) | Compositions suitable for the production of injectable perfusion | |
Riess | Highly fluorinated systems for oxygen transport, diagnosis and drug delivery | |
KR101910213B1 (ko) | 부분불소화된 알칸을 포함하는 수중유형 에멀젼 | |
JPH03502693A (ja) | 高度にフッ素化された有機化合物の改良されたエマルジョン | |
US20160243237A1 (en) | Emulsions of perfluorocarbons | |
JPH06509022A (ja) | 炭化フッ素および親油性/親フッ素性有機化合物を含む調製物、ならびにそれらの用途 | |
EP3258850B1 (en) | Contrast imaging agent with dissolved gas-evolving fluid | |
DE68928349T2 (de) | Fluorkohlenstoffemulsionen mit gesättigten phospholipidemulgatoren | |
JP2007519732A (ja) | 2,6−ジイソプロピルフェノール(プロポフォール)の水性医薬組成物およびその使用 | |
KR890002204B1 (ko) | 퍼플로로탄소 유제, 그의 제법 및 그 유제를 포함하는 수성 약제 조성물 | |
Frenzel et al. | Characterization of a novel hafnium-based x-ray contrast agent | |
JPH10505319A (ja) | 肺に障害を持つ哺乳動物の通常の呼吸を補助する方法 | |
JPS5832829A (ja) | 血管造影剤 | |
JP6936226B2 (ja) | フルオロカーボンナノエマルジョンの組成物 | |
LU87115A1 (fr) | Parenterale suspensionen | |
CN103893114B (zh) | 一种稳定的可注射的维生素d受体激动剂药物组合物及其制备方法 | |
JPH08310971A (ja) | 超音波診断用造影剤 | |
Klamerus et al. | Composition of cardioplegic solutions used in nine medical centers | |
JPS5946230A (ja) | 造影剤 | |
Shaffer et al. | Liquid ventilation. | |
JPH02149531A (ja) | 脳腫瘍内移行改善剤 | |
JPS58110522A (ja) | 血管造影剤 | |
TWI246927B (en) | One kind of concentrated emulsion containing Paclitaxel (taxane) | |
Pugh et al. | Bull's Eye Maculopathy Due to Sildenafil Citrate (Viagra) Toxicity in a 49 Year–Old Female Patient |